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ABSTRACT 
HOT-MELT MIXING OF PARTIALLY MISCIBLE ACTIVE 




Solid dispersion/solution processes for producing pharmaceutical oral dosages such as 
hot-met extrusion (HME) have received increasing attention by industry and academe 
because they can enhance drugs’ solubility and even bioavailability to a great extent by 
converting drugs from crystalline to amorphous form. HME can be carried out at two 
process temperature regimes: one where Tprocess > Tm of the drug and the Tg of the 
polymer (or the Tm for the case of semi-crystalline polymers); the other at Tm > Tprocess > 
Tg (Tm for the case of semi-crystalline polymer). Processing below the drug’s melting 
point in the second case has the advantage of reducing potential for degradation.  
Broader applications of HME are often limited by two technical challenges. One 
is that the active pharmaceutical ingredient (API) or the polymer may degrade at the 
elevated temperatures during extrusion processing. To avoid this problem and yet obtain 
a well-mixed solid dispersion/solution, HME needs to be carried out in an optimal 
processing window, where the temperature is kept safely below the degradation 
temperature but is high enough to enhance API’s dissolution in the polymer. Another 
challenge is the possible physical instability of the extrudate during its shelf life. The 
API’s solubility is decreased significantly once the temperature is dropped from the HME 
processing temperature to room temperature. As a result, the drug may recrystallize from 
the polymeric matrix. It is rather challenging to experimentally determine the API’s 
solubility in the polymer and there are only few published articles in this area. In this 
ii
dissertation, solid dispersions of a model drug acetaminophen (APAP) and a 
pharmaceutical grade polymer poly(ethylene oxide) (PEO) were prepared by using hot-
melt mixing (HMM), a process closely related to HME. APAP’s solubility in PEO at 
HME processing temperature was measured utilizing a novel rheological characterization 
technique, hot-stage microscopy and differential scanning calorimetry (DSC). The results 
from the three methods were consistent and the solubility was found to increase from 
14% at 80 ºC to 41% at 140 ºC. A “phase diagram” was constructed based on the 
experimental data and could be explored to design the HME process and formulation.  
The apparent drug solubility at room temperature was estimated to be less than 
10% via glass transition temperature (Tg) measurements using DSC and dynamic 
mechanical thermal analysis (DMTA), scanning electron microscopy (SEM), and X-ray 
diffraction (XRD). A model using the Flory-Huggins interaction parameter χ estimated 
from the “phase diagram” was utilized to predict the room temperature solubility. The 
drug’s solubility in the amorphous portion of PEO was estimated to be 11.7% at 300 K. 
Since PEO is a semi-crystalline polymer with crystallinity of about 80%, the actual 
solubility is around 2.3%, consistent with apparent solubility estimation.  
A new method to determine APAP’s solubility at temperatures below the PEO’s 
melting temperature was developed by observing the number of spherulitic nuclei, 
growth rate and the “quality” of the spherulites under polarized optical microscopy 
(POM). At 30 
o
C, the solubility was determined to be less than 1%, while at 50 
o
C the 
solubility was 10%.  The nucleation constant Kg, fold surface free energy σe and work of 
chain folding q were calculated using the Hoffman-Lauritzen (HL) theory and it was 
found that the chain folding of PEO became more difficult in the presence of APAP.  
iii
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1.1 Background Information 
One of the major challenges for the pharmaceutical industry is that more than 40% of 
marketed drugs are poorly water soluble
[1]
 while the percentage of insoluble newly 
developed chemical entities in pharmaceutical chemical laboratories is up to 60% of the 
total.
[2]
 As a result, solid dispersion technologies such as hot-met extrusion (HME) and 
spray drying have become more popular because they can enhance the drugs’ solubility 
and even bioavailability to a great extent by converting drugs from crystalline to 
amorphous solution form.
[3-5]
 An example of solubility enhancement is given in Figure 
1.1, which shows the improvement of piroxicam dissolution rate after the spray-drying 
process.
[6]
 Plasma concentration of a drug substance in beagle dogs demonstrates 




Figure 1.1  Dissolution profiles of (a) Piroxicam, (d) physical mixtures of piroxicam and 







Figure 1.2  Mean plasma concentrations in dogs (n=4) after oral administration of 50 mg 
capsules. The samples from top to bottom are 20% melt-extruded drug-PVP K30 solid 
dispersion, 30% melt-extruded drug-PVP K30 solid dispersion and 20% crystalline drug 




Chiou and Riegelman have defined solid dispersion as “a dispersion of one or 
more active ingredients in an inert carrier at the solid state, prepared by the melting, the 
solvent or the melting solvent method”.
[8]
 Formulation of poorly soluble compounds as 
solid dispersions might lead to particle size reduction, improved wetting, reduced 
agglomeration, changes in the physical state of the drug and desirably dispersion on a 
molecular level, according to the physical state of the solid dispersion. Nowadays, the 
term solid dispersion is mostly linked to glass solutions of poorly soluble compounds, 
using amorphous carriers with high glass transition temperatures. There are a large 
variety of pharmaceutically approved polymers available for solid dispersion purpose, 
including polyvinylpyrrolidone (PVP)
[9, 10]
 and its co-polymers poly(ethylene-co-
vinylacetate) (PVP/VA),
[11, 12]
 polyethylene  oxide (PEO),
[13, 14]
 hydroxypropyl 
methylcellulose acetate succinate (HPMCAS),
[15, 16]





 etc. A list of carriers used for hot-melt extrusion dosage forms 











Table 1.1  Carriers Used to Prepare Hot-melt Extrusion Dosage Forms
[20]
 
Chemical Name Trade Name Tg (
oC) Tm (
oC) 
Ammonio methacrylate copolymer Eudragit® RS/RL 64 - 
Poly(dimethylaminoethylmethacrylate-
co-methacrylic esters) 
Eudragit® E  50 - 
Poly(methyl acrylate-co-methyl 
methacrylate-co-methacrylic acid) 
Eudragit® 4135F 48 - 
Poly(methacrylic acid-co-methyl 
methacrylate) 1:2 
Eudragit® S 160 - 
Hydroxypropyl cellulose Klucel® 130 - 
Ethyl cellulose Ethocel® 133 - 
Cellulose acetate butyrate CAB 381-0.5 125 157 
Cellulose Acetate Phthalate - 165 192 
Poly(ethylene oxide) Polyox® WSR -67 65-80 
Poly(ethylene glycol) Carbowax® -20 37-63 
Poly(vinyl pyrrolidone) Kollidon® 168 - 
Poly(vinyl acetate) Sentry® plus 35-40 - 
Hydroxypropyl methylcellulose phthalate - 137 150 
Polyvinylpyrrolidone-co-vinyl acetate Kollidon® VA64 - - 
Hydroxypropyl Methylcellulose Methocel® 175 - 
Hydroxypropyl Methylcellulose Acetate 
Succinate 
Aqoat-AS® - - 
Poly(lactide-co-glycolide) PLGA - - 
Polyvinyl Alcohol Elvanol® - - 
Chitosan Lactate Sea-Cure® - - 
Pectin Obipektin® - - 
Carbomer Carbopol® 974P - - 
Polycarbophil Noveon® AA-1 - - 
Poly(ethylene-co-vinyl acetate) Elvax® 40W -36 45 
Polyethylene - -125 140 
Poly(vinyl acetate-co-methacrylic acid) CIBA-I - 84-145 
Epoxy resin containing secondary amine CIBA HI 80-100 - 
Polycaprolactone - - - 
Carnauba Wax - - 82-85 
Ethylene-vinyl acetate copolymer Evatane® - - 
Glyceryl Palmitostearate Precirol® ATO 5 - 52-55 
Hydrogenated Castor & Soybean Oil Sterotex® K - - 
Microcrystalline Wax Lunacera®Paracera® - - 
Corn Starch - - - 
Maltodextrin - - - 
Pregelatinized Starch - - - 
Isomalt Palatinit® - 145-150 
Potato Starch - - - 
Citric Acid - - 153 
Sodium Bicarbonate - - - 
Methacrylic acid copolymer type C Eudragit® L100-55 - 104.4 
Chitosan - 203 - 
Xanthan gum - - - 
Agar - - - 
Povidone Plasdone® S-30 - - 
Lactose - - 201 
Microcrystalline cellulose Avicel® PH 101 - - 





Recently, some new solid dispersion formulations have entered the market (Table 
1.2): Kaletra (Abbott), Intelence (Tibotec), Certican (Novartis), Isoptin SR-E (Abbott), 
Nivadil, Prograf (Fujisawa Pharmaceutical Co., Ltd) and Rezulin (Sankyo). All of these 
new formulations utilize amorphous polymers as a carrier. A particular type of solid 
dispersion is solid solution, where the API is dispersed on a molecular level in the 
amorphous polymer. 
 
Table 1.2  Examples of Commercially Available Solid Dispersions
[21]
 
Brand Name Manufacturer Drug Carrier 
Gris-PEG Pedinol Pharmacal Inc. Griseofulvin PEG6000 
Cesamet Valeant Pharmaceuticals Nabilone PVP 
Kaletra Abbott Lopinavir, ritonavir PVPVA (Copovidone) 
Sporanox Jassen Pharmaceutica Itraconazole HPMC 
Intelence Tibotec Etravirin HPMC 
Certican Novartis Everolimus HPMC 
Isoptin SR-E Abbott Verapamil HPC/HPMC 
Nivadil 








Developed by Sankyo, 
manufactured by Parke-Davis 
division of Warner-Lambert 
Troglitazone PVP 


















1.2 Mixing, Processing Temperature and Additives 
Hot-melt extrusion (HME) is a process that involves mixing an active pharmaceutical 
ingredient (API) particulate with a molten, water soluble polymeric excipient in 
processing machines with one or more rotating screws. Figure 1.3 is a schematic diagram 
of twin-screw extrusion. As compared to spray drying (Figure 1.4), HME has the 
advantage of being continuous, solvent free, and easy to scale up. There are basically two 
laminar flow mixing mechanisms in the extrusion process.
[23]
 The first is dispersive 
mixing, which involves the reduction of the size of a component having cohesive 
character, within the continuous molten excipient phase. The component in HME may be 
solid agglomerate if the processing temperature is below the melting point of the API, or 
a dispersed liquid phase if the processing temperature is above the melting point of the 
API. The cohesive character of the agglomerate is due to van der Waals forces between 
the particles of the agglomerate, to the surface tension and elastic properties of the liquid 
droplets, and to the surface tension of the gaseous bubbles. The second is distributive 
mixing of components through flow, which stretches the interfacial area elements 
between the components lacking a cohesive character and distributes them throughout the 
volume. In distributive mixing, one not only needs to stretch the interfacial area, but also 
to reorient it for effective mixing, as well as to randomize the interfacial elements 
throughout the volume. The mechanisms of mixing of miscible and immiscible liquids 
are depicted in Figure 1.5, and that of hard solid agglomerates with liquids in Figure 1.6. 
In the former, elongational and shear stretching is the dominant mechanism, while in the 










Figure 1.5  Schematic representation of (a) laminar distributive mixing where the 
miscible blob is stretched and deformed and distributed throughout the volume; (b) shows 









Figure 1.6  Dispersive mixing of hard solid agglomerates with liquids that, after breakup, 




As mentioned above, the HME process can be conducted in two temperature 
regimes: one where Tprocess > Tm of the drug and the Tg of the polymer (or the Tm of the 
polymer for the case of semi-crystalline polymers); the other is Tm > Tprocess > Tg (or the 
Tm of the polymer for the case of semi-crystalline polymers). The first case is illustrated 
as Figure 1.5 and the second case is illustrated in more details as Figure 1.7. After the 
drug and polymer particles are fed into an extruder or a batch mixer, the polymer starts to 
melt due to the conductive heat from the barrel, and the frictional and plastic energy 
dissipation, resulting in a suspension with drug particles.
[19]
 If the drug exhibits enhanced 
solubility in the water soluble polymeric excipient at the elevated processing temperature 
of the HME process, then the suspended API crystals will begin to dissolve. A dissolved 
liquid API layer is formed at the surface of the crystalline API. That layer is wiped away 
by the laminar flow of the HME process, promoting faster dissolution as the old polymer 




the boundary layer, and the size of the suspended particles diminishes until the particles 
dissolved completely. 
 
Figure 1.7  Schematic representation of the morphological changes of the drug and 




There are many literature papers that used the first case processing temperatures 
(Tprocess > Tm and Tg).
[25-29]
 The four heating zones in the twin-screw extruder that 
Patterson et al. used for carbamazepine (Tm of 190 
o
C) and PVP/VA 64 (Tg of 107 
o
C) or 
PVP/VA 37 (Tg of 55 
o
C) (1:2 w/w) are 80-100 
o

















C for dipyridamole (Tm 
of 163 
o
C) and polymers. All products were extruded at approximately 10 rpm. Qi et al. 








C and screw 
speed of 100 rpm.
[31]
 Generally speaking, the risk of degradation is higher in the first case 
considering that many APIs have very high Tm. Processing below the APIs’ melting 
temperatures in the second case above has the obvious advantage of reducing the 









the processing temperature increased from 152 to 157 
o
C, indicating the complete 
dissolution of crystalline drug at higher processing temperature.
[18]
 Nevertheless, 157 
o
C 
was still 5 
o
C below the drug’s melting point. Besides, one could lower the temperature 
even more for smaller drug loading samples. DiNunzio et al. were able to achieve 
amorphous dispersion of hydrocortisone (Tm of 218 
o
C) in PVP/VA 64 (1:9 w/w) at the 









 E PO at 140 
o
C with the speed of 200 rpm.
[32]
 The extrudate strands produced 
containing 10% of API were clear while the strands produced containing 20% were 
opaque. When Tprocess < Tm of the drug, drug’s solubility at that temperature determines if 
one can achieve a miscible melt-mixed product. The solubility topic will be discussed in 
more details below. 
Sometimes it is unavoidable to use plasticizers in order to reduce the Tg of a 
polymer (if Tdegradation < Tg), and therefore reduce the extrusion processing temperatures. 
Plasticizers also lower the melt viscosity and thus, lower the shear forces needed to 
extrude a polymer, thereby improving the process of certain high molecular weight (high 
viscosity) polymers.
[33, 34]
 Plasticization of the polymer is generally attributed to the 
intermolecular secondary forces between the plasticizer and the polymer. The free 
volume between polymer chains is increased by plasticizers, which leads to Tg and melt 
viscosity reduction. Plasticizers used for pharmaceutical dosage forms must have good 
stability, polymer-plasticizer compatibility and permanence, avoiding shelf life 
migration.
[20]
 Triethyl citrate (TEC),
[35-37]
 and low molecular weight polyethylene 
glycols
[34, 38, 39]
 are the common plasticizers used for pharmaceutical extrusion. The 




are dependent on the permanence of the plasticizers. Permanence of a plasticizer during 
processing and storage is very important and the evaporation of highly volatile 
plasticizers from the dosage form during storage has been studied and reported. Repka 
and McGinity demonstrated that the amount of plasticizer remaining in hot-melt extruded 
films over time was a function of the plasticizer type and storage conditions.
[34]
 In 
transdermal films, the addition of a plasticizer can improve the film’s flexibility.
[34]
 It is 
interesting that several drug substances have been reported to function as plasticizers in 
the hot-melt extrusion process.
[40-42]
 CO2 has been injected into the extruder at 
supercritical pressures, dissolved in the melt, and used as a temporary plasticizer in the 
HME.
[43]
 At the die of the extruder, expansion occurs to atmospheric pressure which 
results in a transformation of CO2 to the gaseous phase. As a consequence, CO2 escapes 
from the extrudate and is not present in the final product. 
The elevated temperatures needed to process unplasticized or plasticized 
polymers may lead to polymer degradation. The stability of polymers that are susceptible 
to degradation can be improved with the addition of antioxidants, acid receptors and or 
light absorbers during HME. One manufacturer of these materials recommends the 
incorporation of an antioxidant into formulations containing low molecular weight 
hydroxypropylcellulose.
[44]
 Similarly, poly(ethylene oxide) has been reported to be 
protected from free radical and oxidative degradation by the incorporation of one or more 
antioxidants.
[45]
 This will be discussed in greater detail in the next chapter on material 
properties.  
Antioxidants are classified as preventive antioxidants or chain-breaking 




act to prevent initiation of free radical chain reactions. Reducing agents, such as ascorbic 
acid, are able to interfere with autoxidation in a preventive manner since they 
preferentially undergo oxidation. The preferential oxidation of reducing agents protects 
drugs and polymers from attack by oxygen molecules. These antioxidants are sometimes 
referred to as oxygen scavengers. They are most effective when used in a closed system 
where oxygen cannot be replaced once it is consumed. Chelating agents such as edetate 
disodium (EDTA) and citric acid are another type of preventive antioxidant that decrease 
the rate of free radical formation by forming a stable complex with metal ions that 
catalyze these reduction reactions.
[20]
  
Hindered phenols and aromatic amines are the two major groups of chain 
breaking antioxidants that inhibit free radical chain reactions. Commonly used 
antioxidants such as butylated hydroxyanisole, butylated hydroxytoluene and vitamin E 
are hindered phenols. Because the O-H bonds of phenols and the N-H bonds of aromatic 
amines are very weak, the rate of oxidation is generally higher with the antioxidant than 
with the polymer. Other materials have been used to facilitate HME processing. Waxy 
materials like glyceryl monostearate have been reported to function as a thermal lubricant 
during hot-melt processing. Vitamin E TPGS has been reported to plasticize polymers 
and enhance drug absorption.
[45, 46]
 
The efficiency of the HME process does not depend only on the API and polymer 
material properties mentioned above. It also depends on extruder design variables and 
process variables, such as screw rpm, barrel set temperature profiles, residence time 
distribution and flow rate. Researchers have used very low rotating speeds such as 10 
rpm
[30]
 to high speeds such as 200 rpm
[32]




materials processed. Qian et al. extruded a model drug (Tm of 160 
o
C) with PVP/VA 64 
(Tg of 107 
o
C) (4:6 w/w) at 150 
o
C, and they compared the speed between 50 and 225 
rpm.
[47]
 A micro phase-separation of the drug and polymer was observed under the 
Raman mapping after the samples were stored for 2 months (Figure 1.8). Liu et al. melt-




 E PO (Tg of 53
 o
C) (3:7 w/w) at 
different rotating speed and temperatures.
[19]
 It was found that at 140
 o
C, indomethacin 
was able to totally dissolve in E PO at 20 rpm. At 100 and 110
 o
C, however, a screw 
speed of 100 rpm was needed for a full dissolution. In the work of this dissertation, only 
the results from 50 rpm are presented. The reason is that when Tprocess > Tm
mix
 (drug’s 
dissolution temperature, details will be discussed in Chapter 3.1), melt-mixed samples 
were transparent, indicating the drug was well-mixed and completely dissolved in the 
polymer. The other reason why only one rotating speed was used in this dissertation is 
that for the particular API-excipient system, acetaminophen and poly(ethylene oxide), 
material properties are the main determining factor on miscibility and shelf-life stability.  
The processing conditions are far less important compared to the thermodynamics of 
mixing and therefore, the focus is placed on the latter. 
In practice, the mean residence time in the twin-screw extruder ranges from one to 
10 minutes.
[48-50]
 It is desirable to shorten the residence time during processing to reduce 
the risk of degradation.
[12]
 A long residence time of 10 minutes was used in this work for 





Figure 1.8  Raman mapping of drug-PVP/VA processed at (a) 50 rpm; and (b) 225 rpm. 






1.3 Challenges of HME 
Solid dispersions/solutions with a wide range of API release profiles can be manufactured 
via HME, considering the richness of the polymer chemistry and the powerful mixing and 
shaping capability of the extrusion process. A new graft copolymer Soluplus
®
 has been 
developed specifically for the purpose of pharmaceutical HME.
[51]
 Besides instant-release 
oral formulations,
[10, 18, 19, 52, 53]
 HME-prepared solid dispersions/solutions can also be 







 With the same formulation, the release rate of 
chlorpheniramine maleate (CPM) is lower for HME samples as compared to powder 
compressed samples (Figure 1.9).
[61]
 
Although the extrusion technology has been realized by the pharmaceutical 
industry since 1971 (Figure 1.10), broader applications of HME are often limited by two 
common technical challenges. One is that the APIs may degrade at the elevated 




obtain a well-mixed dispersion of API and polymer, the extrusion needs to be carried out 
in an optimal processing window, where the temperature is kept safely below the API’s 
degradation temperature and kept in the HME equipment for a short time. Another 
challenge is the potential physical instablility of extrudate during its shelf life, which 
involves the API’s recrystallization from the amorphous solid solution achieved at the 
Tprocess through HME. The API’s solubility can decrease significantly once the 
temperature is dropped from the HME processing temperature to the storage temperature, 
e.g., ambient temperature. As a result, the API may phase separate from the polymeric 
matrix and recrystallize.
[47, 62]
 Different strategies can be applied to address this issue 
depending on the specific application and the material system. One common way to 
prevent recrystallization is to select a suitable polymer for a given API.
[9, 63-65]
 However, 
considerable development time is needed to identify the appropriate formulations 





might also help to inhibit API’s  recrystallization. 
 
 
Figure 1.9  Chlorpheniramine maleate (CPM) release profiles from directly compressed 
(left) and HME (right) samples in 900 ml of 0.1N HCl (♦), pH 4.0 acetate buffer (◊), pH 
4.0 citrate buffer (▲), pH 4.0 phosphate buffer (Δ), pH 6.8 phosphate buffer (■) and pH 












To address the aforementioned two challenges, it is critical to determine 
experimentally the API’s solubility in a polymeric excipient at both processing and 
storage temperatures. There are very few publications devoted to such solubility studies, 
all of which utilized only amorphous polymers with high glass transition temperature (Tg) 





powder mixtures were heated at very slow rates using a differential scanning calorimeter 
(DSC) to determine the depressed melting points (Tm
mix
) of the APIs. Phase diagrams 
were plotted between the Tg of the polymer and the melting point (Tm) of the pure API, 
from which the API’s solubility at HME processing temperature could be read (Figure 
1.11-1.13). The method requires an “appreciable” thermal effect associated with the API 
dissolution process in order to determine Tm
mix
. None of the studies provide direct 
experimental data regarding the solubility in highly viscous PVP and PVP/VA at room 
temperature. The difficulty lies in the fact that the kinetics of reaching the drug-polymer 
equilibrium are extremely slow. 
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Figure 1.11  Melting point (Tend) and glass transition (Tg) of (a) indomethacin (IMC) and 




Figure 1.12  DSC thermograms of physical mixtures of indomethacin with increasing 
volume fraction of PVP K12 measured at a heating rate of 1 
o
C/minute. Onset of the 
melting (□), offset of melting (◊) and predicted melting point depression for an athermal 




Figure 1.13  DSC thermograms of physical mixtures of itraconazole with increasing 
volume fraction of Eudragit® E measured at a heating rate of 1 
o
C/minute. Onset of the 
melting (□), offset of melting (◊) and predicted melting point depression for an athermal 







A more fundamental understanding of the miscibility of API-polymer mixtures is 
much needed for the pharmaceutical industry to embrace solid dispersion/solution 
technologies such as HME. Theoretically, the miscibility of any two components is 
governed by their Gibbs free energy of mixing (∆Gm). 
 STHGm ∆−∆=∆   (1.1) 
The entropy of mixing (∆S) is usually larger than zero and favors the mixing. 
Negative enthalpy of mixing ∆H is beneficial for miscibility and solid dispersion 
stabilization.
[65, 75-77]
 ∆S is represented by the molecule size difference between the API 
and the polymer. The larger the difference is, the larger the ∆S. ∆H is represented by the 
intermolecular interaction between API and the polymer. The stronger the interaction is, 
the more negative the ∆H. The entropic and enthalpic effects on ∆Gm will be discussed in 
greater detail in Chapter 4.3.3. Based on this simple understanding of the 
thermodynamics, much effort has been devoted to understand the role of API-polymer 
molecular interactions and how they affect the drug’s solubility in the polymer and its 
stability. However, beyond the above basic understanding, very limited literature 
references have discussed theoretical methods that can be applied to predict API’s 
solubility in polymers and the stability of the solid dispersions/solutions. The studies that 
determined the APIs’ phase diagram at high temperatures use the Flory-Huggins model to 
calculate APIs’ activities or solubilities in polymers with the interaction parameter χ 
estimated from the melting point depression.
[70-74]
 Theoretical treatment of polymer 




 in 1942. The Flory-
Huggins theory is based on the lattice model shown in Figure 1.14. In the case of the low 




molecules have roughly the same volumes, each occupies one lattice site. With the 
polymeric solvent, Figure 1.14b, a segment of the polymer molecule has the same volume 
as a solute molecule and also occupies one lattice site.   
  
(a)                                                               (b) 
Figure 1.14  Lattice model of solubility: (a) low molecular weight solvent; (b) polymeric 
solvent. ○, Solute; ●, Solvent. 
 
By statistically evaluating the number of arrangements possible on the lattice, 
Flory and Huggins obtained an expression for the entropy of mixing in forming a solution 
from N1 moles of solute and N2 moles of solvent: 
 
)lnln( 2211 φφ NNRS +−=∆
 
(1.2) 
where the φ1 and φ2 are volume fractions of solute and solvent, respectively.  
An expression for the enthalpy of mixing was obtained by considering the change 
in the adjacent-neighbor (molecules or segments) interactions on the lattice: 
 ∆H = RTχN1φ2 (1.3) 
















a   (1.4) 
where 1φ  is the volume fraction of the drug, 2φ  is the volume fraction of the polymer, m 
is the molar volume ratio of a polymer molecule to a drug molecule, and χ is the Flory-
Huggins interaction parameter. The theoretical background on how to calculate activity 
and solubility can be found in Chapter 4.3.1.  
It was found that the model fits reasonably well the activities of indomethacin and 
nifedipine dissolved in PVP, PVP/VA and polyvinyl acetate (PVAc) (Figure 1.15), but 
works poorly with D-mannitol in PVP.
[70]
 Two studies conducted by the same group 
show that often predicted drug solubility in PVP and its derivatives is lower than the 
experimentally obtained values.
[71, 73]
 To explain the discrepancy, the authors postulated 
that the kinetic factor also contributes to the inhibition of drug recrystallization, which is 
not included in the Flory-Huggins model.  
 
Figure 1.15  Activity a1 of (a) indomethacin (IMC) and (b) nifedipine (NIF) versus 








1.4 Semi-crystalline Polymers 
All previous literature studies address only few selected amorphous polymers. Not only it 
is necessary to test the melting point depression methodology on more polymers to 
understand its applicability, it is also of considerable fundamental and practical interest to 
find out whether this widely used model can be used to understand the drug’s solubility 
in semi-crystalline polymers. This is a more complicated topic because true solutions are 
formed between the API and the molten polymer (above Tm
mix
), and during cooling of the 
extrudate the dissolved API may interfere with the polymer chain folding involved in the 
crystallization process. 
Semi-crystalline polymers such as poly(lactic acid) (PLA), poly(vinylidene 
fluoride) (PVDF) and poly(ester amide) (PEA) are often used in medical devices and 
biodegradable implants.
[80-82]
 Poly(ethylene oxide)s (PEOs) with molecular weight (MW) 
of 1,500-20,000 g/mol, often referred as polyethylene glycol (PEG), are widely used for 
the preparation of oral solid dispersions for dissolution rate and bioavailability 
improvement.
[14, 83, 84]
 High MW (>100,000 g/mol) PEOs, on the other hand, are often 
chosen for the HME process because of their broad processing window
[13]
 and they have 
been used in applications such as sustained-release matrix systems, transdermal drug 
delivery systems, and mucosal bioadhesives.
[33, 38, 59, 67]
 In semi-crystalline polymers, 
drug diffusion can be hindered due to the presence of crystallites.
[85]
 The volume fraction 
and the size of the crystallites may affect the diffusion coefficient, and the influence of 
these parameters is expressed in terms of tortuosity factors.
[86-88]
  
 The semi-crystalline polymer excipient used in this thesis is a relatively high MW 










 and block 
copolymers
[102]
 has been extensively studied over the past decades. In the miscible blend 
system of poly(acetoxystyrene)(PAS)/PEO, the presence of the amorphous PAS phase 
reduced the spherulitic growth rate of PEO (Figure 1.16).
[94]
 The crystallization ability of 
PEO increased with increasing PAS content as indicated by the decreasing nucleation 
constant kg and surface free energy of the chain folding of PEO σe. Details on how to 
measure these kinetic parameters can be found in Chapter 4.5.1. In other miscible blend 
systems, however, the crystallization rate of PEO was found to decrease more 
significantly in the presence of strongly interacting polymers as compared to weakly 
interacting polymers.
[95, 99]
 Figure 1.17 demonstrates that at the same crystallization 
temperature, PEO blends with the strongly interacting random copolymers of ethylene 
and methacrylic acid (EMAA, 55wt% acid units) and styrene and hydroxystyrene (SHS, 
50wt% hydroxystyrene) crystallize much slower than PEO blends with weakly 
interacting poly(methyl methacrylate) (PMMA).
[95]
 The long period of PEO, which is the 
sum of the thickness of the crystalline lamellae and amorphous layer, increased by 2-4 
nm for the PMMA/PEO blends, an effect associated with interlamellar diluent placement. 
In the immiscible poly(ε-caprolactone) (PCL)/PEO blends, where both polymers are 
semicrystalline, the crystallization rate of PEO decreased with increasing amount of 
PCL.
[97]
 The authors considered the slow-down of the crystallization rate to be caused by 
the physical restriction to the growth of crystalline PCL domains. In the silica-PEO 
nanocomposite system, the distribution of particle spacings in the semicrystalline state is 
always significantly broader than in the melt, even though the mean particle spacing is 
unchanged.
[100]




“force” the nanoparticles “defects” out of their way to crystallize in a minimally 
perturbed form (Figure 1.18). Reversible de-intercalation and intercalation processes 
were detected in PEO-Cloisite 15A (material properties will be discussed in Chapter 2.3) 
nanocomposites during secondary crystallization and subsequent melting of the 










Figure 1.17  Wide angle X-ray diffraction (WAXD) measured crystallinity as a function 









Figure 1.18  Crystallization in the presence of brush-coated nanoparticles. In well-
dispersed nanocomposites, the growing lamellae can maneuver the nanoparticles, thereby 






Figure 1.19  Schematic representation of the morphology in the PEO/Cloisite
®
 15A 





The drug-PEO system studied in this thesis is more complicated than the miscible 
polymer blends, immiscible blends and nanocomposite systems. The drug’s physical 
state, size, and miscibility with PEO, all play important roles in PEO’s crystalline 
morphology, spherulite growth rate, and nucleation. One may be able to determine the 
APIs’ solubility by observing the morphological change, spherulitic growth rate and 








Acetaminophen (APAP), also called paracetamol, is the active ingredient in Tylenol
®
 
(Figure 2.1). It is used to relieve mild to moderate pain from headaches, muscle aches, 
menstrual periods, colds and sore throats, toothaches, backaches, and reactions to 
vaccinations (shots), and to reduce fever. Acetaminophen may also be used to relieve the 
pain of osteoarthritis (arthritis caused by the breakdown of the lining of the joints). 
Acetaminophen is in a class of medications called analgesics (pain relievers) and 
antipyretics (fever reducers). It works by changing the way the body senses pain and by 
cooling the body.
[103]
 When taken at recommended doses, APAP has an excellent safety 
profile, notably lacking the gastrointestinal (GI) side effects of aspirin and ibuprofen.
[104]
 
However, acute overdosaging with acetaminophen, whether accidental or deliberate, is 
relatively common and can be very serious. Ingestion of 10-15 g of acetaminophen by 










Crystalline APAP has two common polymorphs, which are the monoclinic (form 
I)
[106]
 and the orthorhombic (form II).
[107]
 Monoclinic APAP is thermodynamically more 
stable at room temperature with respect to the orthorhombic modification.
[108]
 The APAP 
synthesized by the manufacturers is in form I. Form II was shown to be more soluble
[109]
 
and directly compressible into tablets.
[110]
 Despite considerable effort by researchers, its 
production in pure form from solution has remained elusive.
[111]
 Figure 2.2 shows 
microscope pictures of monoclinic and orthorhombic APAP growing from different 
polymer solutions.
[112]
 Their X-ray diffraction (XRD) patterns also exhibit distinct 
differences shown in Figure 2.3.
[112]
 The melting point of the monoclinic form is 170 ºC 
and of the orthorhombic form is 158 ºC based on the DSC results (Figure 2.4). The raw 
crystalline and the recrystallized APAP in this thesis is in the monoclinic form and 
therefore the polymorphism will not be further discussed. 
  
Figure 2.2  Monoclinic APAP growing from beads of butyl methacrylate/isobutyl 





Raw acetaminophen was purchased from Spectrum Chemicals (Gardena, CA) and 
was used without further purification. It is a white powder and the crystals are of rod 
shape, with the length of one particle about 100 µm (Figure 2.5a). Since the particles are 




(Figure 2.5b). The molecular weight of APAP is 151.19 g/mol and the density is 1.293 
g/cm
3
. The glass transition temperature of amorphous acetaminophen is 24.5 ºC (Figure 
2.6). 
 






Figure 2.4  Melting peaks of monoclinic (top) and orthorhombic (bottom) acetaminophen 





















Figure 2.6  Glass transition of amorphous APAP determined from 2
nd
 heating of 
crystalline APAP in DSC.  
 
 
APAP’s solubility in water is 14.9 mg/g at 25 ºC
[113]
 and 23.7 mg/g at 37 ºC.
[114]
 
According to the biopharmaceutical classification system (BCS),
[115]
 acetaminophen is a 
BCS class III drug,
[116]
 which has high solubility in the aqueous medias over the pH range 
of 1 to 7.5 but low intestinal permeability. Grattan et al. showed that the addition of 





concentration in plasma even though the dissolution profiles were similar.
[117]
 This 
example shows that even though formulation change may seem completely innocuous, it 
may very well alter the plasma profile if the new excipient alters GI physiology. 
Thermogravimetric analysis (TGA) of APAP was performed in air and N2 
environments (Figure 2.7). Degradation onsets of the two curves are very close, and 
APAP is thermally stable until 177 
o
C (higher than its Tm of 170 
o
C) in N2 environment. 
The hot-melt mixing temperature of 120 
o
C used in this thesis (Chapter 3.1) is well below 
the 177 
o
C and, thus, safe for APAP processing. 
 
Figure 2.7  Weight loss of APAP during TGA at 10 
o
C/minute heating rate in air (solid) 
and N2 (dashed). 
 
 
2.2 Poly(ethylene oxide) 
Poly(ethylene oxide) (PEO) is a semi-crystalline polymer and is often chosen as the solid 
dispersion excipient for HME because of its broad processing window.
[13]
 Polyethylene 
glycols (PEGs) with molecular weight of 1,500-20,000 g/mol, which are smaller 




are often used for the preparation of oral solid dispersion for dissolution rate and 
bioavailability improvement.
[14, 83, 84]
 PEG 300 (MW of 280-320 g/mol) and PEG 400 
(MW of 380-420 g/mol) are widely used in injectable formulations when pH adjustment 
alone is insufficient in achieving the desired solution concentrations.
[118]
 High MW PEO 
has been used in applications such as sustained-release matrix systems, transdermal drug 
delivery systems, and mucosal bioadhesives.
[33, 38, 59, 67]
 The influence of PEO molecular 
weight on the dissolution profiles are illustrated in Figure 2.9, showing that the drug 
release rate is slower by using higher MW PEO.
[56]
 The PEO used in this thesis is in 
powder form and is kindly donated by the Dow Chemical Co. (Midland, MI). It is a 
POLYOX
TM
 Water-Soluble resin and is a nonionic polymer. The company markets 
different PEO grades with molecular weights ranging from 100,000 to about 8,000,000 
g/mol. WSR N10 is the one used in this thesis, whose weight average molecular weight 




Figure 2.8  Chemical structure of PEO. 
 
The melting and glass transition temperatures of PEO are 62.5 ºC (Figure 2.10) 
and -56.6 
o
C (Figure 2.11), respectively. The degree of crystallinity is about 80%, based 
on the heat of fusion of the “perfectly” 100% crystalline PEO being 203 J/g.
[119]
 TGA of 
PEO was performed in air and N2 environments (Figure 2.12). Unlike APAP, PEO is 




more severe than that in N2. To prevent PEO from such degradation, N2 purge was used 
during the hot-melt mixing in this work (Chapter 3.1). 
 
Figure 2.9  Dissolution profiles of hot-melt extruded mini-matrices containing 30% 
metroprolol tartrate (MPT) and 70% hydrophilic polymer: PEG 6000 (■), PEO 100,000 
















Figure 2.12  Weight loss of PEO during TGA at 10 
o
C/minute heating rate in air (solid) 
and N2 (dashed). 
 
The oxidative degradation of powdered PEO resin was studied by Scheirs et 
al.
[120]
 Powdered PEO readily oxidizes under mild ageing conditions (60°C) owing to its 
large surface area, its weak crystalline lattice and the weak carbon-oxygen bonds in its 




about 23 days and, in the extreme cases, the free-flowing powder is transformed into a 
soft wax. With increasing oxidation, there is also a pronounced change in the morphology 
of PEO from a spherulitic to an axialitic structure. This transition is due to oxidatively 
induced changes in molecular weight and dispersity that affect the crystallization 
conditions. The emergence of multiple DSC melting peaks after oxidation indicates that a 
number of low-melting, low-molecular-weight fractions are formed as a result of chain 
scission processes. Such degradation was not observed in the current study because all 
powdered PEO was stored in a sealed container at room temperature, supported by the 
evidence of a single DSC melting peak (Figure 2.10) and the fact that the powder 
remained free-flowing. N2 purge was used during hot-melt mixing (HMM) to reduce the 
chance of oxidation degradation. The morphology of quenched HMM-prepared PEO is 
spherulitic with spherulite size, depending on crystallization temperature Tc, as large as 
1mm, indicating a pure, not degraded sample (Figure 2.13). In practice, antioxidants such 
as Vitamin E and its derivatives, Vitamin C (ascorbic acid) and butylated hydroxyanisole 
(BHA) have been used in pharmaceutical preparations and these compounds have been 









Two commercial nanoclays, Cloisite
®
 15A and 30B were received as samples from 
Southern Clay Products (Gonzales, TX). Cloisite
®
 15A is a natural montmorillonite 
(MMT) modified with dimethyl, dehydrogenated tallow and quaternary ammonium 
cations, while Cloisite
®
 30B is a montmorillonite modified with bis-(2-hydroxyethyl) 
methyl tallowalkyl ammonium cations (Figure 2.14). Cloisite
®
 nanoclays are surface 
treated to be compatible with a whole host of systems. Cloisite
®
 15A is the most 
hydrophobic and Cloisite
®
 30B is the most hydrophilic member in the surface treated 
Cloisite
®
 family (Figure 2.15). A Cloisite
®
 particle of 8 microns contains over 1,000,000 
platelets stacked together. Extremely large interfacial area between the clay and the 
polymer can be obtained if the platelets can be separated, that is exfoliated, from each 
other after the clay is processed together with a polymer. Because of this unique property, 
nanoclays have the potential of being used in the polymer industry to slow down the 
diffusion of gaseous molecules through various polymers, creating “barrier” films or 
enclosure structures. 
   
HT: hydrogenated tallow (~65% C18; ~30% C16; ~5% C14) 
T: tallow (~65% C18; ~30% C16; ~5% C14) 
 
Figure 2.14  Chemical structures of Cloisite
®








Figure 2.15  Cloisite
®




Three types of polymer layered silicate nanocomposites may be obtained while 
nanoclays are incorporated into the polymer, as illustrated in Figure 2.16.
[123]
 When the 
polymer is unable to intercalate between the silicate sheets, a phase-separated composite 
is obtained, whose properties stay in the same range as that of traditional 
microcomposites. On the other hand, in intercalated nanocomposites, the insertion of a 
polymer matrix into the layered silicate structure occurs in a crystallographically regular 
fashion, regardless of the clay to polymer ratio.  In such structures, a well-ordered 
multilayer morphology built up with alternating polymeric and inorganic layers is 
generated. Normally, only a few molecular layers of polymer can be intercalated in these 
materials.
[124]
 Small angle X-ray scattering (SAXS) results show that at 2% Cloisite
®
 15A 
loading, the silicate nanoparticles entered into the PEO lamellae, increased the lamellae 
thickness while decreasing the distance between two lamellae (Figure 2.17).
[125]
 At 4% 
loading, however, nanoparticles gathered in the amorphous regions between lamellae, 









Figure 2.16  Different types of composites from the interaction of layered silicates and 











Figure 2.17  Small angle X-ray 
scattering (SAXS) measured (a) The 
long period, (b) lamellae layer 
thickness, (c) amorphous layer 
thickness and (d) the volume fraction 
of semi-crystalline material of pure 
PEO and the PEO/montmorillonite 
(MMT) nanocomposites with 2 and 
4%MMT during isothermal 














 First of all, there is significant 
morphological difference between PCL/Cloisite
®





 unmodified sample (Figure 2.19). The observed black lines in Figure 
2.18 cannot be interpreted as individual silicate layers as they are too large and thick. The 
size and shape of the lines in the TEMs supports the view of intercalated stacks. In 
contrast, Cloisite
®
 type MMT without surfactants cannot be intercalated and the original 
MMT stack is fully preserved even after mixing with PCL. These clay aggregates are 
larger, less diffuse and darker as compared to the intercalated, and most likely partially 
broken-up stacks seen in Figure 2.19. The second finding is that all nanocomposites 
display a pronounced decrease in amorphous layer thickness as shown in Figure 2.20, 
which is a signature of secondary crystallization via the insertion of new crystals in 
between already existing ones. Primary crystallization is defined as the growth of 
spherulites, involving primary crystals in rather open “primary stacks”. Behind the 
spherulitic growth front another one follows much slower, involving further and delayed 
conversion of amorphous material that was left amorphous in the primary stacks by the 
insertion of new crystals. The overall crystallinity is significantly improved in the 












Figure 2.19  TEM of poly(ε-caprolactone) +8% Cloisite
®









Figure 2.20  Small angle X-ray 
scattering (SAXS) measured (a) The long 
period, (b) lamellae layer thickness, (c) 
amorphous layer thickness and (d) the 
volume fraction of semi-crystalline 
material of pure PCL and the PCL/MMT 
nanocomposites during isothermal 












 30B, on the other hand, formed exfoliated 
nanocomposites with no clear SAXS peaks of PEO (MW 100,000) (Figure 2.21) and 
lower PEO crystallinity.
[127]
 Park et al. have developed a method of inserting and 
stabilizing donepezil molecules in the interlayer space of clay via mono or double layer 
stacking (Figure 2.22).
[128]







-laponite (LA), whose chemical formulae can be found in their paper.
[128]
 By 
making hybrids where donepezil molecules intercalated into the smectite clays, 
controlled release drug delivery systems were achieved (Figure 2.23).  
 









Figure 2.22  Schematic diagrams of the arrangement of the intercalated donepezil in 






Figure 2.23  Release profiles of donepezil in pH 1.2 HCl from the Eudragit
®
 E coated 








3.1 High Temperature Solubility Measurement 
3.1.1 Sample Preparation – Hot-melt Mixing (HMM) 
The APAP-PEO mixture samples with twelve APAP weight percentages of 0, 1, 2, 3, 4, 
5, 10, 20, 25, 30, 40, 50 and 60% were prepared by hot-melt mixing under a N2 purge 
blanket using a Brabender FE-2000 batch intensive mixer with two counter rotating 
screw melting/mixing elements (Figure 3.1). 50 g of pre-mixed powders was processed 
for each batch at a mixer temperature of 120 ºC and rotor speed of 50 rpm. After 10 
minutes of mixing, the melt was removed from the mixer and compression molded at 120 
ºC into 25 mm diameter × 1 mm thickness discs as well as 14 × 10 × 2.7 mm bars 
separately. The evolution of the torque during mixing of 30%APAP-PEO is given as an 
example in Figure 3.2. The increase of the torque value at the beginning represents the 
feeding surge. After that, the torque value decreases until it reaches a plateau. It takes 
about 5 minutes for the torque to reach a constant value. The drop of the torque is due to 
the viscosity decrease of the mixture, which is caused not only by the melting of PEO, 
but also by the dissolution of the APAP molecules into the highly viscous polymer melt. 
Detailed rheological results are presented in Chapter 4.1.1. Simply put, the dissolved 
APAP acts as a plasticizer and lowers the viscosity of the mixture. A constant torque 
value indicates that 10 minutes is sufficient time for complete mixing. All samples were 
cooled down to 25 ºC with cooling water circulated in the compression mold. They were 





Figure 3.1  Brabender FE-2000 batch mixer with two counter rotating screws. 
 
Figure 3.2  The evolution of torque during melt mixing for 30%APAP-PEO. 
 
As mentioned in Chapter 1, the rotation speed and the residence time have been 
optimized to achieve a well-mixed and homogeneous mixture. 120 
o
C is a safe 
temperature for both APAP and PEO (Figures 2.7 and 2.12). For drug loadings ≤ 30%, 
APAP could completely dissolve in PEO at 120 
o
C (results in Chapter 4.1). For higher 




distributed mixtures and suspensions for the solubility studies. As mentioned earlier, N2 
purge was used to prevent PEO from oxidative degradation (Chapters 1 and 2). All 
processing conditions are fixed as the focus of this thesis is the experimental and 
thermodynamic study of drug-polymer miscibility in HMM-prepared APAP-PEO 
systems of a wide range of APAP concentrations, determined over a wide range of 
temperatures from ambient to processing. 
 
3.1.2 Rheological Experiments 
The Rheometrics Mechanical Spectrometer RMS-800 from Rheometrics Scientific (now 
TA Instruments, New Castle, DE) was used to determine the steady viscosity of PEO and 
its mixtures with APAP. A step rate rotational flow test was conducted at a constant shear 
rate (
•
γ ) of 0.5/s using 25 mm parallel plates. The PEO and APAP-PEO could achieve a 
steady-state stress and thus, viscosity, at this shear rate. A sample disc (25 mm diameter × 
1 mm thickness) was loaded between the plates at 140 °C but was quenched to the testing 
temperatures (Tf) in less than 2 minutes. It was held isothermally at Tf for 15 minutes to 
reach equilibrium before testing. Each sample was tested individually at Tf values of 80, 
100, 120 and 140 °C for 10 minutes.  
A schematic drawing of a parallel plate set-up is presented in Figure 3.3.
[129]
 The 
viscosity η is calculated by measuring experimentally the shear stress τ at a constant 














3.1.3 Hot-stage Microscopy (HSM) 
Mixtures of 10, 20, 30, 40 and 50 wt% of APAP in PEO were examined by hot-stage 
microscopy using an optical microscope (Carl Zeiss Universal Research Microscope) 
equipped with a Zeiss AxioCam MRc5 (5MB-pixel resolution) digital camera and 
coupled with a Mettler FP82HT hot stage and Mettler FP90 temperature controller 
(Mettler-Toledo Inc., Columbus, OH, USA). Samples were heated between two glass 
slides from room temperature to a final temperature (Tf) of 80, 100, 120, and 140 ºC at a 
heating rate of 10 ºC/minute and kept isothermally at Tf for 15 minutes. Images were 









3.1.4 Differential Scanning Calorimetry (DSC) 
DSC measurements were carried out using a TA Instruments Q100 (New Castle, DE) 
equipped with a refrigerated cooling system. The chamber was flushed with N2 at a flow 
rate of 40 ml/minute during testing. A sample of about 4 mg was weighed and placed in 
an aluminum pan with lid and crimp sealed. The glass transition temperatures (Tgs) of 
PEO and APAP were measured in the 2
nd
 heating cycle of a heat-cool-heat loop. Pure 
PEO was heated from 30 ºC to 80 ºC at 10 ºC/minute, quenched to -80 ºC and reheated to 
80 ºC at 10 ºC/minute. Pure APAP powder was heated from 30 ºC to 180 ºC at 10 
ºC/minute, quenched to -25 ºC and reheated to 180 ºC at 10 ºC/minute. 
Binary mixture samples, with 10, 20, 25, 30, 40, 50 and 60 wt% of APAP, were 
examined using the following heat-cool-heat cycle for determination of the glass 
transition temperature Tg of the mixture, which were further utilized to estimate APAP’s 
solubility at high temperatures, i.e., above the PEO’s melting point, and the melting 
temperature Tm of the mixture. 
1: A sample was heated from 30 ºC at 10 ºC/minute to a final temperature (Tf) of 80, 100, 
120 or 140 ºC, at which temperature it was held isothermally for 15 minutes. 
2: The sample was quenched from Tf to -80 ºC at 20 ºC/minute. 




3.2 Apparent Room Temperature Solubility Measurement 
3.2.1 Sample Preparation - HMM 
The same APAP-PEO mixture samples as in Chapter 3.1.1 were used for the 
determination of the apparent room temperature solubility. APAP-nanoclay-PEO 
mixtures, with APAP concentrations ranging from 10, 20 and 30wt%, and nanoclay 
Cloisite® 15A and 30B concentration kept constant at 10wt%, were prepared by using 
the same hot-melt mixing procedure.  
 
3.2.2 DSC 
APAP’s apparent solubility in PEO at room temperature was estimated by Tg 
measurement in a single heating ramp. Samples were stored at room temperature for four 
weeks. APAP-PEO mixtures with APAP concentration varying from 1 to 50% were 
quenched to -80 ºC and then heated to 80 ºC at 10 ºC/minute. The melting temperature 
onset Tm was also recorded in the same cycle. 
 
3.2.3 Dynamic Mechanical Thermal Analysis (DMTA) 
Dynamic Mechanical Thermal Analyzer DMTA-IV from Rheometrics Scientific (now 
TA Instruments, New Castle, DE) was used to determine the Tgs of pure PEO and its 
mixtures with APAP that were stored at room temperature for four weeks after hot-melt 
mixing. The experiment was conducted using a dual cantilever with a small frame. A 
sample bar (14 × 10 × 2.7 mm) was first quenched to -70 °C and then ramped to 30 °C at 
a heating rate of 2 °C/min using liquid nitrogen as a cooling medium and 5 ml/minute N2 
gas to prevent the build-up of moisture during the experiment. A strain of 0.02%, within 




viscoelastic response), and a frequency of 1 Hz were applied for each sample. The elastic 
(in-phase) modulus (E’), viscous (out-of-phase) modulus (E”) and tan δ (E”/E’) were 
recorded during the experiment. Tg was determined from the peak of the tan δ curve in 
the glass transition region. 




=E   (3.2) 
where τ is the stress and γ is the strain. The viscoelastic properties of the APAP-PEO 
systems were studied by dynamic mechanical analysis where a sinusoidal strain was 
applied and the resulting stress was measured. For an ideally elastic solid, the resulting 
stress and the strain will be perfectly in phase. For a purely viscous fluid, there will be a 
90
o
 phase lag of stress with respect to strain.
[130]
 In the dynamic mechanical test, stress 
and strain are expressed as: 
 )sin(0 δωττ += t   (3.3) 
 )cos(0 ωγγ t=   (3.4) 
where ω is the frequency of strain oscillation, t is the time and δ is the phase lag between 
stress and strain. By definition, the elastic (in-phase) modulus E’, viscous (out-of-phase) 

























3.2.4 Scanning Electron Microscopy (SEM) 
Morphologies of binary and ternary mixture samples were examined using a LEO 1530 
Field Emission Scanning Electron Microscope (Carl Zeiss SMT Inc., Peabody, MA) at 2 
keV. Both the surfaces and cryo-fractured surfaces of the samples were characterized. 
The cryo-fractures were prepared by snapping a sample disc that had been soaked in 
liquid nitrogen for 5 minutes. All samples were sputtered with a thin layer of carbon to 
improve the electrical conductivity prior to imaging. 
 
3.2.5 X-ray Diffraction (XRD) 
A Philips PW3040 X-ray diffractometer (PANalytical Inc., Westborough, MA) was 
controlled by X’Pert software with Cu Kα radiation (λ = 1.54 Å) generated from a copper 
source operating at a power level of 40 KV and 40 mA. The sample discs were held 
directly for XRD analysis and scanned over the 2θ range of 5–30º at the step size of 
0.03º/step and the scan rate of 1 second/step. The slit configuration was 1.0º, 1.0º and 
0.1mm for divergence, anti-scatter and receiving slit, respectively. 
 
3.3 Determination of Flory-Huggins χ Parameter from Melting Point Depression 
3.3.1 Melting Point Determination  
The melting point Tm and heat of fusion ∆fusH of crystalline APAP were measured by 
heating APAP from 298.15 K to 473.15 K at a heating rate of 10 K/minute in DSC. The 
polymer-depressed drug’s melting points at different PEO weight percentage, namely 






3.3.2 Determination of Acetaminophen’s Solubility in PEG 400 
APAP’s solubility in PEG 400, a small molecular weight analogue of PEO N10, was 
measured using an Agilent 8453 UV Spectrophotomer (Foster City, CA) at wavelength of 
243 nm. An excess amount of APAP was added to a capped glass bottle containing PEG 
400 maintained at 300 K and was stirred vigorously for 48 hours. The resulting 
suspension was filtered using a Millipore 0.2 µm PVDF syringe filter (Millipore Corp., 
Billerica, MA). Samples were diluted with DI water and the UV readings were compared 
to a calibration curve. 
 
3.4 Dissolution Testing 
Dissolution tests on binary and ternary mixture samples were performed under the sink 
condition using a Distek 2100A USP standard dissolution apparatus with a basket stirrer. 
The dissolution medium (900ml of aqueous buffer solution with pH=7) was maintained 
at 37±0.5ºC and stirred at 50 rpm. At predetermined intervals, 5 ml of solution was 
withdrawn and the volume change was corrected in the calculation. The liquid was 
filtered with a Millipore 0.45µm PVDF filter and analyzed using 10mm quartz cells and 
an Agilent 8453 UV Spectrophotometer (Foster City, CA) at 243nm. Each of the tests 






3.5 Crystallization of PEO and APAP-PEO 
3.5.1 Sample Preparation – Solvent Evaporation 
The APAP-PEO mixtures containing 0, 0.1, 1, 2, 10 and 20% by wt. APAP were 
prepared by dissolving both materials in acetone/water and drying the solution in a 
vacuum oven at room temperature for 24 hours. The dry films were about 140 µm thick 
and were stored in a vacuum desiccator with silica gel before further testing.  
 
3.5.2 Polarized Optical Microscopy (POM) 
Pure PEO or APAP-PEO mixtures were placed on a glass slide and left on a hot plate at 
130 ºC, when both PEO and APAP were fully melted based on results of the solubility 
study at that temperature (Figure 4.8). Since the films were very thin (140 µm), it took 
less than 30 seconds for complete melting (confirmed under polarized light) and ready for 
optical microscope observation. After 30 seconds of heating, the sample was quickly 
transferred to a Mettler FP82HT hot stage (Mettler-Toledo Inc., Columbus, OH, USA) 
that was equilibrated at different crystallization temperature (Tx) (Table 3.1). The 
morphology, number and size of the spherulites were monitored under a polarized optical 
microscope (Carl Zeiss MicroImaging, LLC, Thornwood, NY, USA). The growth of the 
spherulites as a function of time was recorded until spherulite impingement and the 
diameter of the spherulites was measured directly from the monitor screen using the 
length measurement function in AxioVision software. Reported spherulitic growth rates 
(G) were determined as the average rates from 6-12 spherulites of three to six samples. 
The standard deviation on the average growth rates was less than 5% of the magnitude of 




Table 3.1  Crystallization Temperatures Tx Used in POM and Tc Used in DSC 
PEO          
Tx 51 50 49 48 47 46 45 40 30 
Tc 50 48 46 44 42 40    
0.1%APAP-PEO          
Tx 50 40 30       
Tc 52 50 48 46 44 42    
1%APAP-PEO          
Tx 50 40 30       
Tc 52 50 48 46 44 42    
2%APAP-PEO          
Tx 50 49 48 47 46 45 44   
Tc 52 50 48 46 44 42    
10%APAP-PEO          
Tx 50 49 48 47 46 45 44 40 30 
Tc 52 50 48 46 44 42    
20%APAP-PEO          
Tx 46 45 44 43 42 41 40   
Tc 46 44 42 40 38 36    
All values in ºC 
 
3.5.3 DSC 
DSC measurements were carried out using a TA Instruments Q100 (New Castle, DE) 
equipped with a refrigerated cooling system. The chamber was flushed with N2 at a flow 
rate of 40 ml/minute during testing. Samples were cut to nearly identical shape, and the 
sample weight was kept low (1.000 ± 0.050 mg) to minimize thermal lag during heating.  
During the isothermal crystallization experiment, a sample was first heated to 130 ºC and 
kept isothermally for 1 minute. It was then quenched to a specific crystallization 
temperature Tc (Table 3.1) and was kept isothermally for a sufficient period to allow 
complete crystallization. The sample was then heated to 90 ºC at 10 ºC/minute to 




Non-isothermal crystallization was carried out by using DSC to determine the 
crystallization temperature (Tcp) and enthalpy (ΔHc). A sample was heated from 25 ºC to 
130 ºC at 10 ºC/minute and kept isothermally for 1 minute to remove the thermal history. 
It was then cooled to 25 
o
C at the rate of 10 ºC/minute and the Tcp was taken as the 





RESULTS AND DISCUSSION 
 
4.1 High Temperature Solubility Measurements 
4.1.1 Determination of Drug Solubility at Elevated Temperatures by Rheological 
Analysis 
 
The objective of the rheological study is to find drug’s solubility at different temperatures 
within the extrusion processing window by tracking the viscosity change of the binary 
mixtures with different drug loadings. The selected testing temperatures are above the 
melting temperature of PEO (~62 ºC) and below the melting point of APAP (~170 ºC). In 
this temperature range, if the APAP is not dissolved in the PEO, it will form a 
suspension. 
In general, steady viscosity (η) of PEO and APAP-PEO mixtures decrease with 
increase in temperature due to increase of polymer chain mobility and reduction of 
intermolecular forces. The viscosity results are plotted against APAP concentration in 
Figure 4.1. The four viscosity curves at different Tf exhibit a similar trend, namely the 
viscosity value drops first with increasing drug loading, and then increases after reaching 
a certain concentration. The viscosity curve at Tf = 140 ºC, as an example, decreases from 
6110 Pa·s for pure PEO to 430 Pa·s for 40 wt% of APAP, after which it climbs up to 691 
Pa·s for 60 wt% of APAP. The initial decrease of viscosity indicates intermolecular force 
weakening due to the drug dissolution.
[131-133]
 That is, the dissolved APAP acts as a 
plasticizer in this case, which leads to decrease of the viscosity with the increase of drug 




occurs when the drug solubility limit is exceeded and the undissolved solid drug particles 
act as suspended fillers. Extensive previous studies, starting with Einstein,
[134]
 have 
shown that the viscosity of a filler-polymer melt suspension system depends on the 
interfacial energy as well as the filler’s concentration and shape.
[135-138]
 Generally 
speaking, the viscosity increases with the filler’s concentration,
[139-141]
 which can be 
explained by the increased viscous “drag” and dissipation due to the suspension and 
particle/particle interactions at high concentrations. An example of the solid filler effect 
is presented in Figure 4.2, where the zero-shear viscosity of PP(polypropylene) increases 





Figure 4.1  Viscosity η curves of 0, 10, 20, 25, 30, 40, 50 and 60% APAP in PEO at 
temperatures (Tf) of 80 ºC (Δ), 100 ºC (□), 120 ºC (◊) and 140 ºC (○). 
 
  






















The viscosity data are further fitted with fifth-degree polynomial only to 
determine the minimum value. Theoretically, the drug concentration with the lowest η is 
the drug solubility at the specific temperature Tf. Dotted curves in Figure 4.1 were 
obtained from polynomial fitting with R
2
>0.99 and the drug solubility values determined 
from the fitting curves are listed in Table 4.1. The result shows that the drug solubility 
increases steadily with temperature. It should be mentioned that the predicted solubility at 
80 ºC (22%) may be slightly higher than the real value because the viscosity values of 20, 
25 and 30 wt% of APAP are very close to each other, which makes it more difficult to 
identify the critical point. These solubility data obtained by such a simple rheological 
experiment is an original contribution of this thesis work and is of great value for 
determining the processing window of HME. For example, to prepare a fully miscible 
APAP-PEO system with drug loading of 20%, the lowest processing temperature is 100 
ºC. Otherwise, the drug crystals will not fully dissolve into the polymer melt no matter 
how intensive or how long the mixing is.  
 
Figure 4.2  Zero-shear viscosity η0/ηp vs. filler volume fraction φ1. The solid data points 
represent the simulation results based on Einstein’s theory. The open triangles represent 
the experimental results using PP (polypropylene) and CaCO3 treated with stearic acid. 






Table 4.1 Summary of APAP Solubility in PEO at Elevated Temperatures Measured 
with The Rheometrics Mechanical Spectrometer, Hot-Stage Microscope and DSC 
Temperature 
Solubility by rheological 
evaluation (%) 
Solubility by hot-stage 
microscopy (%) 
Solubility by DSC 
(%) 
80 ºC 22 10 - 20 14 
100 ºC 24 20 - 30 20 
120 ºC 31 30 - 40 30 
140 ºC 41 40 - 50 n.a. 
 
 
A low shear rate (0.5 s
-1
) was used in the rheological study so that the materials 
remained as Newtonian flows under the testing conditions. If a high shear rate was used, 
the materials would exhibit non-Newtonian behavior such as shear thinning, where the 
viscosity would decrease with increasing shear rate. Shear thinning would diminish the 
viscosity difference between samples with different APAP concentrations, which would 
make it difficult to determine the minim on the viscosity curves in Figure 4.1. 
 
4.1.2 Optical Determination of Drug Solubility at Elevated Temperatures  
To check the solubility data obtained from the rheological test, a hot-stage microscope 
(HSM) was used to directly observe the physical state of the drug particles in the molten 
polymer mixtures. The same temperatures (Tf) as those in rheological experiments were 
used. To facilitate observation and assure intimate contact between two materials, PEO 
and APAP were first hot-melt mixed. The sample was placed on a glass slide, slightly 
heated on the hot stage, and pressed carefully with a cover glass. The mixture was further 
equilibrated at the temperature of interest. At Tf of 80 ºC and APAP loading of 10% 
(Figure 4.3a), crystalline APAP fully dissolves in the molten PEO with no visible 
particles observed. In contrast, at a drug loading of 20%, APAP crystals can be found 








Figure 4.3  Hot-stage microscopic images of samples after being kept isothermally at 
different temperatures for 15 minutes. a) 10% APAP-PEO at 80 ºC; b) 20% APAP-PEO 
at 80 ºC; c) 20% APAP-PEO at 100 ºC; d) 30% APAP-PEO at 100 ºC; e) 30% APAP-
PEO at 120 ºC; f) 40% APAP-PEO at 120 ºC; g) 40% APAP-PEO at 140 ºC; h) 50% 




80ºC should fall between 10 and 20%. Experiments were also conducted at 100, 120 and 
140 ºC (Figure 4.3c-h) and the results are summarized in Table 4.1. Clearly, most 
solubility data obtained from rheological tests fall into the range determined by HSM. 
The only slight mismatch was found at 80 ºC. As discussed in the previous section, the 
critical point on the curve of viscosity versus drug loading cannot be accurately 
determined at 80 ºC because the transition is not sharp enough. It should be mentioned 
that the optical microscopy method is an approximate method and cannot be applied to 
accurately identify the solubility value. Nevertheless it is quite straightforward, readily 
accessible, and can be applied to obtain an “engineering” estimate of the solubility. 
Another advantage is that the microscopy method, being straightforward, can be applied 
to a wide range of drug-polymer systems compared to other analytical methods. 
 
4.1.3 Determination of Drug Solubility at Elevated Temperatures Using DSC 
A third approach using DSC was explored to determine the drug solubility at high 
temperatures. The method is based on the assumption that the glass transition temperature 
should vary with APAP’s concentration in the APAP-PEO solution. Similarly to the 
rheological and microscopic analyses, temperatures within the HME processing window 
were selected, namely 80, 100, 120 and 140 ºC. In the 1
st
 heating cycle, the sample was 
heated to a final temperature Tf and then held at the temperature for 15 minutes. 
Depending on the drug loading and the temperature, the crystalline drug may be partially 
or fully dissolved in the molten polymer at Tf. The sample was then quenched to -80ºC, a 
temperature below the glass transition temperatures of both PEO and APAP. In the 2
nd
 




Tg of PEO and APAP are -56.6 ºC and 24.5 ºC, respectively. Glass transition 
temperatures of amorphous APAP-PEO from the 2
nd
 heating cycle are plotted in Figure 
4.4. One interesting finding is that the Tg behavior for Tf = 80, 100 and 120 ºC shows 
quite a similar trend. Tg increases with APAP concentration but the glass transition 
temperature stops rising after a certain drug loading. When the APAP concentration is 
less than the critical value, APAP particles fully dissolve in the molten polymer at Tf 
during the first heating scan. Beyond that limit, no more crystalline APAP can dissolve in 
PEO and, thus, the curve reaches a plateau (in the case of 140 ºC, Tg dips at the region of 
high drug loading, which will be discussed later). Hence, the critical concentration is 
taken to be the drug’s solubility at Tf. The solubility data were summarized in Table 4.1. 
It should be mentioned in this juncture that one assumption for the DSC method is that 
the drug does not recrystallize during the quench and the second heating scan. The fact 
that the solubility values predicted by all three methods are very close to each other in 
this temperature range seems to support this assumption. Overall, the data show that the 
solubility increases from 14% at 80 ºC to 41% at 140 ºC.  
 
Figure 4.4  Glass transition temperatures of mixtures at different drug loading 
determined from the 2
nd
 heating cycle in DSC with the ending temperatures (Tf) in the 1
st
 


























The following peculiar phenomenon is found on the curve corresponding to Tf of 
140 ºC: the Tg drops as much as 17 ºC when the drug loading increases from 30% to 40%. 
It is known from the rheological and microscopic analysis that drug solubility is around 
41% at 140 ºC. Thus, the sharp Tg decrease is not caused by drug recrystallization or 
phase separation. To further investigate this issue, the Fox equation
[142]
 was used to 
calculate the theoretical glass transition temperatures for APAP-PEO with different drug 












+=   (4.1) 
where w1 and w2 refer to the weight fraction and Tg1 and Tg2 refer to the glass transition 
temperatures of the drug and polymer, respectively.  
The Fox equation, as well as the Gordon Taylor (GT) equation expressed as 
Equation (4.2),
[143]
 are often applied to predict the glass transition temperature of random 
copolymers
[144-146]
 and plasticized polymers
[147-149]












=   (4.2) 
where wi is the weight fraction and Tgi the glass transition temperature of the blend 
component i and K is an arbitrary fitted parameter. Ideal volume additivity was assumed 
for the repeat units in the copolymer and the plasticizer-polymer blend for both of the two 
original equations. Under that assumption, K is defined as the ratio of the differences of 
the coefficients of expansion at Tg of the glassy state and rubbery state. Unlike the Flory-
Huggins theory as discussed in Chapter 1, neither the Fox nor the GT equation takes 




These two semi-empirical equations have been applied to drug-polymer and drug-
salt systems to study the miscibility of the binary components.
[76, 150-153]
 The Tg values of 
these systems often do not agree with the GT predictions made on the assumption of ideal 
mixing. A positive deviation was observed in the sodium indomethacin (NaIMC) and 
indomethacin (IMC) system as shown in Figure 4.5.
[152]
 The influence of molecular 
interactions on the Tg of nonideal binary polymer blends has been explained in terms of 
the relative magnitude of two different interaction energies: the interactions between like 
molecules, or homo-contacts, and those between unlike molecules, or hetero-contacts.
[154]
  
When the interaction between the hetero-contacts dominates the overall energies of the 
system, the nonideally mixed system will have a Tg that is greater than that which would 
be expected from the GT prediction. This appears to be the case for the NaIMC and IMC 
solid solution. Because the GT prediction for an ideally mixed system is based on the 
assumption that the free volume of the individual components is additive, a nonideal 
system with a Tg value greater than that predicted from the ideal system would be 
expected to have a free volume that is smaller than that of the ideal system. This is 




Figure 4.5  Tg of coprecipitated sodium indomethacin (NaIMC) and indomethacin (IMC) 


















 which was most likely to be caused by the strong intermolecular 






Figure 4.6  Tg of HME-prepared indomethacin and Eudragit
®
 E measured by DSC (●) 




Since the APAP solubility is about 41% at 140 ºC, Tg is only calculated for 
samples having less than 40% APAP loading. As shown in Figure 4.7, most experimental 
Tg values are significantly higher than the theoretical values, suggesting possible specific 
physical interactions between APAP and PEO. When APAP concentration is 40%, 
however, the theoretical Tg is able to match the experimental value. The hydroxyl group 
of acetaminophen is a good proton donor and can form strong hydrogen bonds with the 
oxygen acceptor on the PEO chain,
[155, 156]
 which is capable of leading to a nonlinear 
relationship between Tg and the composition. Strong intermolecular interaction is usually 
beneficial for miscibility and solid solution stabilization,
[65, 75, 77]
 but the H-bonding in the 




According to Wen et al., the high flexibility of PEG and the high mobility of the 
functional groups involved in the H-bonds is the reason why the crystallization of APAP 
cannot be inhibited.
[157, 158]
 The unusual drop of Tg at drug concentration between 30 and 
40% may be due to the saturation of hydrogen bond at high drug concentration.  
 
Figure 4.7  Calculated (◊) and DSC determined (Δ) glass transition temperatures of 
APAP-PEO. Experimental data were obtained from the 2
nd
 heating cycle in DSC with the 
final temperature (Tf) in the 1
st
 heating cycle of 140 ºC. 
 
4.1.4 Phase Diagram of the APAP-PEO System 
Figure 4.8 shows the relationships of polymer-depressed melting point of APAP Tm
mix
 
and melting point of PEO Tm(PEO) with different APAP concentrations. APAP’s 
solubility in the range of 80 to 120 ºC was determined by DSC analysis, while the 
solubility at 140 ºC was estimated to be 41% based on the rheological evaluation method. 
Tm(PEO) values were acquired from the 2
nd





















Figure 4.8  Dissolution temperature Tm
mix
 (□) and PEO melting point Tm (◊) of APAP-
PEO with different percentage of APAP dissolved. 
 
The composite figure of Tm
mix
/Tm(PEO)  vs. drug loading (Figure 4.8) is, in 
essence, a “phase diagram”. Such “phase diagram” may provide valuable information for 
API-excipient formulation and HME process development. HME is often processed at 
temperatures above the Tm(PEO) curve where PEO is in the molten state. APAP and PEO 
are fully miscible and form a liquid solution in region A. In region B, however, APAP 
does not totally dissolve in PEO, and thus the system contains solid suspended drug 
particles. In order to obtain a true solution, it is more favorable to process the mixture in 
region A as compared to region B. Of course, other factors such as the potential of 
thermal degradation need to be taken into consideration.  
Insightful information regarding the mixture’s physical state can be obtained by 

































Understandably, each method has its own limitations. The rheological method can only 
be applied to study the upper range of the processing temperature due to the instrument’s 
toque limitations. More specifically, rheometers generally can only be applied to study 
the system at a temperature higher or significantly higher than the melting temperature of 
the polymer excipient. For solubility determination, the temperature also needs to be 
lower than the melting point of the pure drug. Otherwise, the drug will exist as a liquid 
and increase of drug loading will lead to decrease of the viscosity of the mixture even if 
the drug liquid is not fully miscible with the molten polymer. On the other hand, the 
advantage of the rheological method lies in the relative simple relationship between the 
viscosity and the mixture composition, which makes easy to identify the critical point in 
the viscosity vs. composition curve, i.e., the solubility point range, compared to the DSC 
method. The rheological data themselves are of great interest for process optimization as 
well. The microscopic method allows for a straightforward observation of the physical 
state of the materials. However, it is almost impossible to determine the exact solubility 
due to resolution limitations. The solubility data can also be determined from the shift of 
the glass transition temperature measured via DSC. The DSC method also provides other 
valuable information, such as the melting point of the mixture. However, one has to be 
careful when using the trend of the glass transition temperature to determine the drug’s 
solubility because it is not uncommon for a drug-polymer mixture to have a complicated 
and non-monotonic relationship between the Tg and the composition, such as the one at 






4.2 Apparent Room Temperature Solubility Measurements 
4.2.1 Estimation of Apparent Drug Solubility at Room Temperature via DSC and 
DMTA 
 
Apparent APAP solubility in PEO at room temperature was estimated with similar Tg 
evaluation method described in the previous DSC Section 4.1.3. The difference is that 
samples were stored at room temperature for four weeks before testing, and the Tg was 
determined during the first heating scan. In other words, the Tg value reflects the 
mixtures’ physical state at room temperature instead of the state at elevated temperatures. 
Glass transition temperatures were determined by using both DSC and Dynamic 
Mechanical Thermal Analysis (DMTA) methods. It should be mentioned that the system 
has probably not reached thermodynamic equilibrium after four weeks at room 
temperature, although the recrystallization does drop to an almost undetectably slow rate 
by that time. Hence, the solubility obtained is an “apparent” solubility, which may be 
higher than the thermodynamic solubility. In real application though, it is required by the 
FDA to perform the long-term stability testing in order to examine the shelf-life of any 
pharmaceutical products. Therefore, the experimentally measured “apparent” solubility at 
room temperature can provide sufficient information.  
DMTA is a thermo-analytical technique. While DSC detects the change in heat 
capacity when a polymer changes from the glassy to the rubbery state, DMTA detects the 
temperature when a change of modulus occurs. Tg is determined from the peak of the 
mechanical loss tanδ, which is responsible for dissipation of energy during deformation 
and is defined as: 




where E’ is the elastic modulus and represents how much energy the polymer stores, and 
E” is the viscous modulus and indicates the polymer’s ability to dissipate energy as heat. 
These moduli relate to the stiffness of the material and to its damping capacity (energy 
dissipation).  




































Figure 4.9  DMTA measured elastic modulus (E’), viscous modulus (E”) and tan δ of 
PEO. 
 
The peak of the tan δ is the center of the Tg relaxation while in DSC the onset 
temperature of the Tg relaxation is usually reported. In such a case the DSC Tg will be 
lower than that obtained from DMTA. In addition, a “frequency effect” puts the 
mechanical (ca. 1 Hz) Tg higher than that for a DSC measurement (0.0001 Hz).
[159]
 The 
DMTA determined Tg of pure PEO is -44.3 ºC (Figure 4.9), while the Tg from the DSC 
measurements is -56.6 ºC. Despite of the difference in absolute numbers, both methods 




APAP-PEO sample is observed. For DSC, Tg increases from -51.2 ºC for 1 wt% of APAP 
to -38.7 ºC for 10 wt% of APAP and basically remains constant afterwards. DMTA data 
show a similar trend: Tg first increases with APAP loading, but then reaches a plateau at 
the concentration around 5%. As presented in Figure 4.10, the critical turning point is 
around 10% for DSC and 5% for DMTA. More evidence of APAP recrystallization after 
the sample is cooled from the HME processing temperature to room temperature will be 
presented in the next few sections. 
 
Figure 4.10  Glass transition temperatures of 4-week old melt-mixed APAP-PEO 







































4.2.2 APAP Recrystallization Observed under Scanning Electron Microscopy (SEM) 
Freshly made disc samples with APAP ≤ 30% have a light yellow color, the same as pure 
PEO processed under the same conditions. However, unlike the pure PEO, the color of 
APAP-PEO mixtures (where APAP >10 wt%) will gradually change to milky white at 
room temperature, suggesting the occurrence of APAP’s recrystallization after 
processing. The rate of the color change is dependent on the APAP concentration: the 
appearance of 20-60% APAP-PEO changes appreciably within several hours, whereas it 
takes several days for 10%APAP-PEO samples to exhibit appreciable visual changes. 
SEM photos reveal what happens at the micro scale. Freshly made 10%APAP-PEO has a 
relatively smooth and APAP particle-free surface (Figure 4.11a). On the contrary, drug 
particles, about 1-3 µm in size, are found on the surfaces of 20%APAP-PEO (Figure 
4.11b-c) after the same storage time. SEM images of cryo-fractured surface samples 
suggest that APAP also recrystallizes at the interior bulk of all samples (Figure 4.12). It 
should be mentioned that after 18 days of storage, drug particles appear also at the 
surface of 10%APAP-PEO (Figure 4.13). The size of the recrystallized APAP particles 
does not change over time (Figure 4.14). 
The recrystallization of APAP from a solid dispersion or solid solution formed at 
the processing temperature following quenching occurs in two stages as indicated by the 
recrystallization rate. For samples with APAP concentration > 20%, the first stage takes 
only several hours, whereas for 10%APAP-PEO, the first stage takes weeks. After the 
first stage, the systems still have not reached thermodynamic equilibrium. Furthermore, 






Figure 4.11  SEM images of freshly-made samples (3 hours after melt mixing) (a) 
10%APAP-PEO; (b) 20%APAP-PEO; (c) 20%APAP-PEO.  
 
  











Figure 4.13  SEM images of 10%APAP-PEO after being stored for 18 days. 
 
   
 
Figure 4.14  SEM images of the surface of (a) 10% (b) 20% and (c) 30%APAP-PEO 











The morphology of the recrystallized APAP particles is of great importance since 
it may affect the drug’s dissolution rate in an aqueous medium. For the APAP-PEO 
system cooled at room temperature, APAP crystalline particles formed from the 
recrystallization process have identical morphologies among samples with different drug 
loadings. The APAP particles are several micrometers in size and are richer in 
concentration at the sample surface (Figure 4.11c) than in the bulk (Figure 4.12a). 
Recently, other research groups have observed similar phenomena in that the 
recrystallization tends to happen at the material surface rather than in the bulk.
[160, 161]
 
Firstly, Wei et al. found that the surface tension of high density polyethylene, a semi-
crystalline polymer, drops a stunning 20% in a small temperature region below the 
melting point.
[160]
 They brought up a hypothesis that the initial small crystal regions 
would act as nanoparticles and locate at the polymer surface and reduce the surface 
tension. The hypothesis was later supported by the results of the statistical modeling of 
Thompson et al.
[162]
 Their results showed that the nanoparticles locate robustly at the 
polymer surface, that is, the probability of finding a nanoparticle in the vicinity of the 
polymer surface is higher than the probability of finding a particle in the bulk. Zhu et al. 
found that the crystal growth at the surface of amorphous griseofulvin, a small molecule 
drug, to be 10- to 100-fold faster than that in the bulk, and they suggested the cause to be 
the molecules at the free surface having higher mobility than bulk molecules.
[161]
  
The APAP loading does not affect the morphology of drug particles formed 
during recrystallization. The cooling rate is another parameter that may affect the 
morphology of recrystallized drug particles. To investigate the effect of the cooling rate 




media:  open air (slow cooling) and liquid nitrogen (rapid quenching). Figure 4.15 
suggests that different cooling rates lead to different morphologies of recrystallized drug 
particles. Dispersed drug particles, of several microns in size, are generated in the slowly-
cooled samples. On the other hand, for the quenched sample, drug molecules grow into 
interconnected snowflake-like structures. The morphological difference may be traced to 
the different nucleation and growth rates of crystallization. The results suggest that the 
cooling rate does affect the drug particle morphologies and needs to be carefully 
considered in practice. In some drug-polymer systems, an extremely fast cooling rate may 
slow down the molecular mobility so much that the recrystallization becomes almost 
undetectably slow. Apparently this is not the case for the APAP-PEO system, a fact 




Figure 4.15  SEM images of 20%APAP-PEO cooled in different media: (a) Air and (b) 
Liquid N2. 
 
APAP recrystallization also happens in APAP-nanoclay-PEO ternary mixtures 
and the recrystallized APAP is of the same size range as in APAP-PEO binary mixtures 
(Figure 4.16). It is unknown at this point whether the ternary system forms a 
microcomposite, an intercalated nanocomposite, or an exfoliated nanocomposite due to 





transmission electron microscope (TEM). It is suspected that a microcomposite was 
formed since no significant change was observed in the X-ray diffraction (XRD) results 
as shown in Figure 4.17. TEM is often used to detect the size of the clay particles and the 
silica layers (Figure 2.18 and 2.19). It is difficult for SEM to perform the same duty and 
that is the reason why the morphologies of APAP-PEO and APAP-nanoclay-PEO show 
little difference. 
In summary, SEM results are consistent with the DSC and DMTA results that 
above 10%, APAP will recrystallize from PEO. Thus, from a recrystallization point of 
view, the results indicate a maximum room temperature solubility of APAP in PEO of 
10%. The size and the shape of the recrystallized APAP particles are independent of the 











Figure 4.16  SEM images of the surface of (a)10%APAP-10%Cloisite15A (b) 
10%APAP-10%Cloisite30B (c) 20%APAP-10%Cloisite15A (d) 20%APAP-
10%Cloisite30B (e) 30%APAP-10%Cloisite15A and (f) 30%APAP-10%Cloisite30B-









4.2.3 Detection of Recrystallization via X-ray Diffraction (XRD) 
Samples with 20 and 30 wt% APAP share the same XRD patterns. Figure 4.17 shows the 
XRD spectra of the binary and ternary APAP-PEO mixtures with 30% drug loading. The 
solid state of APAP has been intensively investigated.
[112, 163]
 In this study, APAP exists 
in monoclinic form in all samples. Consistent with the SEM observations, APAP quickly 
recrystallizes within the first day of storage, after which the recrystallization becomes 
extremely slow, supporting the results discussed above on the second stage of 
recrystallization. APAP crystalline peaks in samples with 10 wt% APAP, on the other 
hand, are very weak and it is difficult to draw any conclusions regarding the 
recrystallization rate (spectra not shown). This, despite the fact that there is evidence of 
very slow recrystallization at that concentration, may be related to the sensitivity of the 
XRD. The detection limit of XRD is about 5% of crystalline material. 
Adding nanoclays into the APAP-PEO mixture dramatically accelerates the 





 15A is the most hydrophobic and Cloisite® 30B the most 
hydrophilic (Figure 2.15). Cloisite
®
 15A is often found to form intercalation 
nanocomposites (Figure 2.18) while Cloisite
®
 30B forms exfoliated nanocomposites 
(Figure 2.21). However, the hydrophobicity and structural difference do not appear to 
play a significant role since the nanoclays have essentially an identical effect on the 
APAP’s recrystallization. Nanoclay particles act as nucleation agents and allow the 
APAP recrystallization process to complete within a much shorter time. No further 
change in APAP’s solid state is observed during the next sixty days, based on the results 




prepare more stable tablets at the concentration which is dictated by the ambient 
temperature solubility. 














































































It should be mentioned that nanoclays can also affect the polymer’s crystallization 
rate to various degrees, depending on the polymer-nanoclay system. For example, the 
addition of silicate layers can induce hetero-phase nucleation and promote the growth of 
polyamide crystallites.
[164]
 Another study has shown that the crystallization kinetics of 
polyamide nanocomposites increase only when clay concentrations are very low, while 
high clay loadings retard the crystallization by restricting lamellae coarsening in PEO.
[165]
 
The clay particles act as a nucleating agent for maleic anhydride grafted polypropylene, 
but do not influence the linear growth rate of spherulites or overall crystallization rate 
significantly.
[166]
 The APAP-nanoclay-PEO is a more complicated system comprising 
several phases, including layered silicate, amorphous APAP and PEO regions, crystalline 
PEO regions and crystalline APAP regions.  
 
4.3 Room Temperature Solubility Prediction using the Flory-Huggins Theory 
4.3.1 Theoretical Background 
This section of the thesis work aims at the theoretical prediction of the drug’s solubility 
in the polymer excipient and, especially, the understanding of the material parameters 
that influence the solubility. The polymer is regarded as a viscous solvent and the 




























]1[ln 11  (4.3) 
Here, x1 is the saturation mole fraction of a solid drug in the polymer, a1 is the 
activity coefficient of the drug in the polymer at the solubility limit, Tm is the drug’s 




temperature, in the current study), ∆fusH is the drug’s heat of fusion at the melting point, 





pp CCC −=∆ ). Herein, liquid drug refers to the amorphous drug. ∆Cp is a 
function of temperature and the data can be found in the early literature.
[11]
 Considering 
that ∆Cp does not change significantly in the temperature range of interest, it is assumed 
to be constant and Equation (4.3) can be rewritten as Equation (4.4). 




















−=   (4.4) 
It is necessary to know the activity coefficient a1 in order to calculate the molar 
solubility x1. Based on the Flory-Huggins lattice theory, the activity coefficient of APAP 
is given by Equation (4.5). 











a   (4.5) 
Here, 1φ  is the volume fraction of the drug, 2φ  is the volume fraction of the 
polymer, m is the molar volume ratio of a polymer molecule to a drug molecule, and χ is 
the Flory-Huggins interaction parameter. Assuming the molar volume of the repeating 
unit in PEO is equal to the molar volume of APAP, that is, a drug molecule (○) occupies 
the same size of the grid as a segment of a polymer (●) does as in Figure 1.14, 
relationships between 21 ,φφ and x1 are expressed by Equation (4.6) 


















= φφ    (4.6) 
The drug’s solubility at a specific temperature can be calculated using Equations 
(4.3-4.5) when the value of χ is known. The interaction parameter χ can be calculated 






 Similarly, the melting point of the drug in the presence of 
polymer can be described using Equation (4.7): 














   (4.7) 
Tm is the melting point of the pure drug, while 
mix
m
T is the melting point of the 
drug mixed with a polymer. The values of mix
m
T  at different compositions have been 
determined from high temperature solubility measurements previously, thereby the 




















4.3.2 Theoretical Calculation of APAP’s Solubility in PEO 
Figure 4.18 is a replot of Figure 4.8 showing the melting points of APAP at different 
polymer concentrations. It is worthwhile to point out that these APAP-PEO samples were 
melt-mixed using a Brabender mixer. As a result, the size of the undissolved dispersed 
APAP phase (Figure 4.14) becomes much smaller than the size of the original drug 
particles (Figure 2.5), which allows the sample to reach equilibrium much faster during 
heating in DSC. In other words, a faster heating rate, as compared to the typical slow 




 can be used. Increasing the scanning 
rate not only saves experimental time, but also, more importantly, prevents the drug from 
thermal degradation. In this thesis work, a 10 
o
C/minute heating rate was used in DSC to 
determine the Tm
mix






Figure 4.18  Melting point of APAP-PEO mixtures Tm
mix
 (□) with different weight 




T  of 86, 80, 69, 59, and 50 PEO wt% are 353, 373, 393, 413 and 432.74 
K, respectively. The melting point and ∆fusH values of pure APAP are determined from 
DSC and are 446.17 K and 29372.3 J/mol, respectively. The polymer-drug molar volume 






























−  values were plotted against 
2
2φ  (Figure 4.19). The 
slope of the linear-fitted curve gives the χ value of -1.65 with R
2
 of 0.970. The drug’s 





















Figure 4.19  Plot of Equation (4.7) for the APAP-PEO system.  
 
The APAP’s mole solubility x1 is calculated to be 98.9 mol% and the weight 
solubility w1 is 11.7 wt% at 300 K. It should be emphasized that 11.7 wt% is the 
solubility in the amorphous portion of PEO. It is believed that much less APAP can be  
dissolved in crystalline PEO, if there is any, than in its amorphous portion.
[171]
 For 
example, gas transport properties in a semi-crystalline polymer such as PEO are usually 
modeled by assuming that the crystals act as an impermeable dispersed phase imbedded 
in a permeable amorphous phase.
[172]
 Assuming there is no APAP molecule dissolved in 
the crystalline regions of PEO, the overall solubility is reduced to 2.3% considering the 
fact that the crystallinity of PEO is around 80% for the PEO used, as determined 
experimentally using DSC. The apparent solubility after a month at room temperature 
was measured to be less than 10% based on previous DSC, DMTA, SEM and XRD 






































reached equilibrium after one month. Nevertheless, the theoretical and apparent solubility 
from experiments are still close. The model was also used to calculate APAP’s solubility 
in liquid PEG, which was compared to the obtained experimental data. The results will be 
presented in a later section. 
 
4.3.3 Free Energy of Mixing: Entropic and Enthalpic Effects 
The Flory-Huggins theory
[78, 79]
 is a natural extension of regular solution theory for 
monomeric liquids to systems involving polymers in the amorphous state. It is a 
celebrated and successful molecularly-based model giving a convenient framework for 
describing the thermodynamic properties of polymer solutions and molten polymer 
mixtures. It represents the volume of a polymer system as a lattice which is divided into 
microscopic sites of the same volume (Figure 1.14). In the APAP-PEO system, one drug 
molecule is assumed to occupy one site, while a polymer molecule occupies m sites. The 
entropy of mixing of a drug-polymer system is smaller than that of a drug-small molecule 
system because there are fewer ways in which the same number of lattice sites can be 
occupied by polymer segments than by small molecules. In other words, mixing of large 
molecules involves smaller entropy of mixing, which is unfavorable for mixing. The free 
energy of mixing ∆Gm for a drug-polymer system can be described by Equation (4.8). 
    





  (4.8) 
Here, N1 is the number of moles of the drug, N2 is the number of moles of the 
polymer, 1φ  is the volume fraction of the drug, 2φ  is the volume fraction of the polymer, 




two terms on the right hand side represent the entropy of mixing, while the third term 
stands for the enthalpy of mixing.  
To investigate the entropic effect on the free energy of mixing, ∆Gm/RT vs. the 
composition at different m values were plotted (χ is fixed at -1.65) in Figure 4.20. The 
value m = 757 represents the PEO used, while m values of 48 and 3 are estimated using 
PEO’s low molecular weight analog PEGs with MW of 6000 and 400 g/mol, 
respectively. The calculation results suggest that ∆Gm/RT varies only slightly with m, 
with ∆Gm/RT (m = 757) > ∆Gm/RT (m = 48) > ∆Gm/RT (m = 3). In other words, the 
change of ∆Gm is not significant when the MW of the polymer changes from 100,000 to 
400 g/mol. 
 
Figure 4.20  Free energy of mixing ∆Gm/RT vs. weight percentage of polymer as 
predicted using the Flory-Huggins theory with different polymer-drug volume ratios m. 
Curves from top to bottom are for m = 757 (PEO used), 48 (PEG 6000) and 3 (PEG 400) 
(χ = -1.65).  
 
The Flory-Huggins interaction parameter χ characterizes the excess energy of 
interaction in solution per one molecule of the solvent. The curves of ∆Gm/RT vs. mixture 



















results show that the Gibbs free energy of mixing increase significantly with increasing χ. 
∆Gm/RT is even positive in part of the χ = 2 curve, suggesting poor miscibility of drug 
and polymer. Negative χ, on the other hand, leads to lower ∆Gm/RT and, consequently, 
better miscibility between the drug and polymer. By comparing Figure 4.20 with Figure 
4.21, it seems that the polymer-drug interaction parameter plays a more important role in 
the polymer-drug miscibility compared to that of the polymer MW. However, it should 
be mentioned that the drug’s solubility in the polymer cannot be determined directly from 
∆Gm/RT. Thus, a direct calculation of drug’s solubility in polymers of different MW and 
χ will be given in a later section.  
 
Figure 4.21  Free energy of mixing ∆Gm/RT vs. weight percentage of polymer as 
predicted using the Flory-Huggins theory with different interaction parameters χ. Curves 
from top to bottom are for χ = 2, 0 and -1.65 (m = 757). 
 
4.3.4 Enthalpic and Entropic Effect on the Drug’s Melting Point Depression 
As mentioned above, χ is a critical parameter which affects the miscibility of a polymer 
and a drug. However, it is difficult to theoretically predict its value. Hence, it is of 



















interaction parameters of a drug with different polymers. Figure 4.22 shows the curves of 
the melting temperature of the drug vs. polymer loading at different interaction 
parameters based on Equation (4.7), which suggests that the melting point depression is 
sensitive to the χ value. In other words, the melting point depression may be used 
experimentally for determination of the χ value and use it as a practical indicator for 
polymer selection to a given API. Similarly to the impact on ∆Gm/RT, the polymer MW 
shows only a small effect on the melting depression (Figure 4.23).  
 
 
Figure 4.22  Melting point depression vs. weight percentage of polymer. The temperature 





















Figure 4.23  Melting point depression vs. weight percentage of polymer. The temperature 
curves are calculated using Equation (4.7) with m= 757 (PEO used), 48 (PEG 6000) and 
3 (PEG 400) from top to bottom (χ = -1.65). 
 
4.3.5 Effect of Polymer MW and χ on APAP’s Solubility in PEO/PEG Excipients 
Assuming that χ as measured from the melting point depression of APAP in PEO N10 
could be extended to estimate the χ in PEG 400 because of the same molecular structure 
of the PEO and PEG, the APAP’s solubility in PEG 400 (Mw = 400 g/mol) at 300K was 
calculated to be 14.6 wt% by using the same χ of -1.65. The predicted solubility of APAP 
in PEO N10 (Mw = 10
5
 g/mol) is less than that in PEG 400, which is caused by the 
reduced entropic contribution to the mixing in the PEO N10 system. Therefore, attempts 
to estimate the solubility of a drug in a polymer by measuring solubility in a low 
molecular weight analogue of the polymer need to be corrected accordingly to avoid 
overestimating the solubility.
[73]
 The analysis specifies how to avoid this. 
In an attempt to verify the validity of this method, the solubility of APAP was 



















experimental solubilities are close, suggesting that the χ value calculated from the 
melting point depression method is a reasonable estimate. 
To understand the broader impact of χ, which is represented by the polymer 
chemistry, and polymer MW on the drug’s solubility, the drug’s solubilities at different χ 
and m values were calculated and are given in Table 4.2. The χ values used here are from 
drug-polymer pairs, including indomethacin-PVP (χ = -1.83), nifedipine-PVP (χ = -0.81), 
and ketoconazole-PVP (χ = -0.12).
[71]
 The results show that the solubility decreases by an 
order of magnitude when χ increases from -1.83 to -0.12, while the very low MW 
polymer (MW=400) only leads to 24-36% higher drug solubility as compared to large 
MW analogue (MW=100,000). It should be noted that process requirements often limit 
the usage of the MW of polymer excipients. Low MW PEG in this case is a liquid and 
cannot be used as the major excipient for solid dosage, while extremely high MW may 
cause difficulty for processing due to high viscosity. Hence, one should focus on the API-
polymer excipient intermolecular interactions rather than the polymer MW to improve 
drug-polymer miscibility. 
 
Table 4.2  Solubility in Drug-polymer Pairs Calculated Using Various Flory-Huggins 
Interaction Parameters χ at Different Polymer MW 
χ -1.83 -1.65 -0.81 -0.12 
wt% in large MW 
polymer (m=757) 
13.1 11.7 6.2 3.3 
wt% in small MW 
polymer (m=3) 






4.4 Dissolution Testing 
The experimentally obtained dissolution rates of APAP-PEO and APAP-nanoclay-PEO 
are much slower than that of pure APAP powder in a capsule, as shown in Figures 4.24-
4.26. It takes less than 30 minutes for powder-form APAP to be fully released into the 
buffer solution, while it takes melt-mixed APAP-PEO 90 minutes and APAP-nanoclay-
PEO more than 360 minutes, an order of magnitude slower than powder form APAP, to 
be fully dissolved. Thus, the hot-melt mixed APAP-PEO samples are controlled-release 
formulations. The standard deviation for each release curve was less than 5% and 
therefore, is not shown. 
 
 
Figure 4.24  Dissolution profiles of (×) APAP powder in capsule, (▲) 10%APAP-PEO-
day 1, (Δ) 10%APAP-PEO-day 169, (♦) 10%APAP-10%CL15A-PEO-hour 1, (◊) 





























Figure 4.25  Dissolution profiles of (×) APAP powder in capsule, (▲) 20%APAP-PEO-
hour 1, (Δ) 20%APAP-PEO-day 160, (♦) 20%APAP-10%CL15A-PEO-hour 1, (◊) 






Figure 4.26  Dissolution profiles of (×) APAP powder in capsule, ( ) 30%APAP-PEO-
hour 1, (Δ) 30%APAP-PEO-day 148, ( ) 30%APAP-10%CL15A-PEO-hour 1, (◊) 















































Storage time shows little impact on the dissolution rate (Figures 4.24-26). For 
example, the Figure shows that the drug release profile on day 1 is essentially the same as 
that on day 169 for sample 10%APAP-PEO. A couple of facts should be mentioned in 
discussing this observation: firstly, in all cases, APAP particles never grow into more 
than several micrometers in size. In other words, the morphology does not change with 
the storage time. Secondly, PEO does not dissolve quickly but swells into a gel in the 
aqueous medium. Subsequently, the gel gradually dissolves and by the time it disappears, 
the drug is fully released. The slow dissolution rate of PEO may thus overshadow any 
changes in the APAP’s dissolution rate during storage. 
Diffusion, swelling and erosion are the most important rate-controlling 
mechanisms of commercially available controlled-release products.
[173]
 In order to 
understand the mode of drug release from PEO matrices, the data (Mt/M∞) are fitted 









  (4.9) 
Mt, M∞, k and n’ are, respectively, the amounts of drug released at time t, the 
absolute cumulative amount of drug released at infinite time, a constant incorporating the 
structural and geometric characteristics of the release device, and the exponent of the 
release kinetics. This semi-empirical equation was used to analyze the first 60% of a 
release curve (Mt/M∞ ≤ 60%). The values of n’ were obtained by fitting drug release data 
to Equation (4.9) using the ordinary least square regression (values ± 95% confidence 
limits) provided by software Polymath 5.1 (Polymath software, Willimantic, CT). It is 




mechanism and, zero order drug release (n’ = 1.0) indicates an erosion-controlled release 




Table 4.3  Fitting Results for Equations (4.9) and (4.10). In All Cases R
2
























n' ± 95% CI 
k1 (% min
-0.5) ± 95% 
CI 
k2 (% min
-1) ± 95% CI 
10%APAP-PEO-day 1 1.02 ± 0.01 -0.16 ± 0.29 1.01 ± 0.05 
20%APAP-PEO-hour 1 0.89 ± 0.06 1.40 ± 1.11 1.25 ± 0.21 
30%APAP-PEO-hour 1 0.89 ± 0.03 1.57 ± 0.61 1.26 ± 0.12 
10%APAP-10%CL15A-
PEO-hour 1 
0.71 ± 0.02 2.13 ± 0.26 0.21 ± 0.03 
10%APAP-10%CL15A-
PEO-day 251 
0.56 ± 0.03 4.16 ± 0.29 0.07 ± 0.03 
10%APAP-10%CL30B-
PEO-hour 1 
0.70 ± 0.01 2.63 ± 0.37 0.21 ± 0.04 
20%APAP-10%CL15A-
PEO-hour 1 
0.67 ± 0.03 3.66 ± 0.61 0.21 ± 0.07 
20%APAP-10%CL15A-
PEO-day 212 
0.71 ± 0.01 2.44 ± 0.24 0.22 ± 0.02 
20%APAP-10%CL30B-
PEO-hour 1 
0.72 ± 0.02 2.63 ± 0.47 0.23 ± 0.05 
30%APAP-10%CL15A-
PEO-hour 1 
0.68 ± 0.01 3.02 ± 0.42 0.24 ± 0.05 
30%APAP-10%CL15A-
PEO-day 213 
0.71 ± 0.02 2.52 ± 0.42 0.25 ± 0.05 
30%APAP-10%CL30B-
PEO-hour 1 





The values of n’ for APAP release are listed in Table 4.3. It is interesting that the 
exponent n’ decreases from 1 for APAP-PEO system to about 0.7 for the APAP-
nanoclay-PEO mixtures, indicating that drug release shifts from erosion dominant to 
anomalous by the addition of nanoclays.  
Another power-law based expression developed by Peppas and Sahlin
[179, 180]
 is 
Equation (4.10) and it can be used to estimate the contributions of drug diffusion and 











  (4.10) 
The first term on the right hand side represents the contribution of drug diffusion 
and the second term the contribution of polymer erosion. The coefficient m’ is the 
diffusion exponent for a controlled release device of any geometrical shape exhibiting 
pure drug diffusion. The value of m’ for the disc (or film) is 0.5 according to Peppas and 
Sahlin. Drug release data are fitted to Equation (4.10) using the software Polymath 5.1. k1 
and k2 are the diffusion and relaxation constants, respectively.  
The results show that the APAP diffusion has a much higher contribution to 
dissolution than polymer erosion (k1 >> k2) (Table 4.3) for the ternary mixtures. The 
difference in drug release mode between the binary and ternary mixtures is postulated to 
be caused by the decrease of wettability with the presence of nanoclays. It should be 
noted that the nanoclays are modified by the suppliers to improve their compatibility with 
polymers. The modified clays are more hydrophobic than the original montmorillonite. 
On the other hand, the contact angle of dissolution medium on the surface of 10%APAP-
PEO is found to be 41º, ten degrees smaller than that on the surface of 10%APAP-




by the presence of Cloisite
®
 clays dramatically slows down the dissolution rate of the 
matrix: for the APAP-PEO system, the full release of APAP and the complete dissolution 
of matrix occur at the same time, roughly one hour since the sample was immersed in the 
solution. In comparison, the matrix of the ternary mixture remains intact even after six 
hours, when all APAP has been released.  
 
4.5 Crystallization of PEO and APAP-PEO 
4.5.1 Theoretical Background 
4.5.1.1 Nucleation and Growth Kinetics Theories.  Spherulitic nucleation 
and growth kinetics can be analyzed using the kinetic nucleation theory expounded by 
Hoffman et al.
[181-185]
 Three regimes for nucleation and crystal growth are predicted by 
this theory caused by different degrees of supercooling. They are represented by the 
schematic drawings in Figure 4.27.
[183, 184]
 In the Figure, G is the growth rate, L is the 
substrate length, b0 is the thickness of the molecular layer, and a0 is the stem width. The 
kinetics in each regime are being controlled by the competition between nucleation and 
growth. In regime I, a single nucleation site takes place on the substrate surface and leads 
to the substrate length being completely covered by a crystallization growth layer. At a 
lower temperature (i.e., higher supercooling, ∆T), regime II growth prevails where 
multiple nucleation sites take place on the substrate. At still larger supercooling ∆T, 
regime III is entered where nucleation on the substrate is so prolific that the distances 
between niches sites (Sn in Figure 4.27b) approximate a stem width. An example of three 
regime experimental crystal growth kinetics is presented in Figure 4.28, which shows 








Figure 4.27  Schematic representation of how polymer crystal growth takes place in three 








Figure 4.28  Experimentally measured linear crystal growth rate of polyethylene 




For each of these regimes, the crystal growth rate is expressed by the following 






















  (4.11) 
where i = I, II or III denotes regimes, ∆T is the degree of supercooling ( 0
m




being the equilibrium melting temperature and Tc being the crystallization temperature, 
U
*
 is the activation energy needed for “reeling in” the polymer molecules (defined 
below) from their melt reptation tube,
[187]
 R is the universal gas constant, T∞ is the 





a temperature correction factor accounting for the change of melting enthalpy with 
temperature, given by 2Tc/(
0
m
T +Tc). The pre-exponential term G0 contains terms that are 
essentially temperature-independent. Each regime has a nucleation constant Kg(i), and 













  (4.12) 
where σ is the lateral surface free energy, σe is the lamellar fold surface free energy which 
is related to the difficulty of the chain to perform folding during crystallization, a0 is the 
stem width (the lattice distance between adjacent planes) as shown in Figure 4. 27, k is 
the Boltzmann constant, and ∆Hf is the heat of fusion per crystal unit volume. 



















)ln(ln   (4.13) 
Kovacs et al.
[188-192]
 have quoted a value of 29.3 kJ/mol for U
*
 while Hoffman et 
al.
[181]
 have suggested that U
*
 has a universal value of 6.28 kJ/mol. Cheng et al. have tried 
both values for PEO and they preferred the former,
[92]
 and consequently this value is here. 
The glass transition temperature Tgs of PEO, 2%, 10% and 20%APAP-PEO are -56.6, -
45.9, -27.5 and -16.2 ºC, respectively. The equilibrium melting temperature 0
m
T  of a 
polymer crystal is defined as the melting temperature of an “infinite stack” of extended 
chain crystals, large in directions perpendicular to the chain axis and where the chain 
ends have established an equilibrium state of pairing.
[193]
 This quantity is one of the most 
important thermodynamic properties of crystallizable chain polymers, as it is the 
reference temperature from which the driving force for crystallization is defined. 0
m


















−+=   (4.14) 
where γ’ is the lamellar thickness factor, which is the ratio of the lamellar thickness to the 
critical nucleus thickness in the crystallization process. The HW equation is based on the 
assumption that the difference between crystallization and observed melting temperatures 
is solely due to the thickening of lamellae formed at the crystallization temperature. 
Because of its straightforward experimental implementation and its analytical simplicity, 
this method has been widely and successfully used for the determination of 0
m





4.5.1.2 Macroscopic Crystallization Kinetics (Avrami Theory).  The celebrated 
Avrami analysis of isothermal crystallization kinetics was originally developed for 
metals
[198-201]
 and later modified by others, for example, by Evans
[202]
, for polymers. The 
resultant equation is 
     1 - X(t) = exp(-Knt
n
)  (4.15)  
where Kn is the overall rate constant for the crystallization process, n is the Avrami 
exponent and X(t) is the crystallinity of the polymer at time t and is calculated from DSC 
isothermal exotherms as 










)(   (4.16)  
where ∆fusH∞ and ∆fusHt are the enthalpies of fusion on complete crystallization and at 




process, and whether growth is controlled by diffusion of polymer through the melt or by 
attachment to the growth surface. Based on Shultz’s summary on the consequence of the 
Avrami theory (Table 4.4),
[203, 204]
 the case n = 4 can only result from spherulitic growth 
from homogeneous nucleation. The analysis involves plotting log[-ln(1-X(t)] as a 
function of log t and determining n from the initial slope and Kn from the intercept.  
 
Table 4.4  Interpretation of Avrami Coefficients
[204]
 
Avrami Exponent Nucleation Type Growth Geometry Growth Velocity 
½ Instantaneous Rod t-1/2 
1 Instantaneous Rod Constant 
1 Instantaneous Disc t-1/2 
3/2 Instantaneous Sphere t-1/2 
 Homogeneous Rod t-1/2 
 Instantaneous Disc Constant 
2 Homogeneous Disc t-1/2 
 Homogeneous Rod Constant 
5/2 Homogeneous Sphere t-1/2 
3 Instantaneous Sphere Constant 
 Homogeneous Disc Constant 
4 Homogeneous Sphere Constant 
 
4.5.2 Equilibrium Melting Temperature 
The HW equation was used to determine the sT
m
0  of pure PEO as well as the APAP-PEO 
mixtures prepared by solvent evaporation. The observed melting temperatures, Tm from 
the DSC 2
nd
 heating are plotted against different crystallization temperatures Tc and 
shown in Figure 4.29. The values of 1/γ’, which are the slopes of the resulting linear 
curves, are 0.17, 0.18, 0.26, 0.20, 0.39, and 0.52 for PEO, 0.1%, 1%, 2%, 10% and 
20%APAP-PEO, respectively. The value of 1/γ’ is between 0 (Tm = 
0
m
T  for all Tcs, the 
most stable crystal morphology) to 1 (Tm = Tc, for the case of inherently unstable 
crystals). The results show that the stability of the PEO crystals decreases dramatically 
with increasing APAP concentration. The equilibrium melting temperature 0
m




increases with APAP concentration, from 67.1 
o
C of PEO to 68.0, 69.6, 69.3, 73.0 and 
78.1 
o
C for 0.1%, 1%, 2%, 10% and 20%APAP-PEO, respectively. The shifting trend of 
0
m
T  is the opposite to that of the miscible polymer blends where 0
m
T  decreases with 
increasing amount of the second polymer.
[94, 205, 206]
 It is also possible that APAP, whose 
Tm is 170 
o
C, starts to recrystallize during the process and contributes to the 0
m
T  increase. 
 
 
Figure 4.29  Hoffman-Weeks plots for PEO, 0.1%, 1%, 2%, 10% and 20%APAP-PEO. 






































































4.5.3 Polarized Optical Microscopy (POM) 
PEO, 0.1%, 1% and 10%APAP-PEO have spherulitic morphologies as evidenced by the 
Maltese cross patterns at Tx of 30 
o
C in Figure 4.30 below. As Tx increases and the 
supercooling ΔT decreases (Txs of 40 and 50 
o
C), more amorphous content is formed in 
the crystals, which makes the texture more open and the Maltese cross patterns weaker. 
Similar phenomena were observed by previous investigations for PEO (MW = 10,500 
g/mol)
[92]
 and PEO (MW = 1,000 g/mol).
[207]
 Figure 4.31 demonstrates the increasing 
“open” texture and weakening Maltese cross patterns of PEO with increasing 
crystallization temperature.
[92]
 The apparent complete destruction of spherulite structure 
for 10%APAP-PEO at 50 
o
C is caused by either inclusion or exclusion of the APAP 




















Figure 4.30  Polarized optical micrographs of spherulites at Tx of 30, 40 and 50 
o
C for 
PEO, 0.1%, 1% and 10% APAP-PEO. The POM field of view in pictures with 500 µm 





























Figure 4.31  The spherulite morphology of PEO (MW 105,000) at different degrees of 
supercooling in the vicinities of regime transitions: (a) ΔT= 18.5K; (b) ΔT=16.5K; (c) 





It is seen from Figure 4.30 that the number of spherulitic nuclei in the 10%APAP-
PEO mixture at Tx of 30 
o
C is substantially higher than that in the pure PEO, 0.1% and 
1% APAP-PEO. The detailed results are summarized in Figure 4.32. At Tx of 30 
o
C, the 
number of nuclei in the 10%APAP-PEO samples is five times of that in PEO, indicating 
that APAP functions as a nucleating agent, denoting the existence/presence of tiny APAP 
crystalline regions, that reduce the free energy required to build new surfaces during 
crystallization. The results strongly suggest that APAP either recrystallizes or forms 
amorphous nanosize clusters
[155]
 because it is oversaturated in the PEO at 30 
o
C. At Tx of 
50 
o
C, the number of nuclei is the same for all samples regardless of the APAP 




seems that 9% of APAP is dissolved when the temperature is raised from 30 to 40 
o
C, 
since the number of nuclei for 10%APAP-PEO and 1%APAP-PEO is the same. The fact 
that 1%APAP-PEO had more nuclei than PEO did at 40 
o
C hinted that the solubility was 
less than 1%. The reason for 1%APAP-PEO to have the same amount of nuclei as PEO at 
30 
o
C was possibly due to the low molecular mobility at that temperature so that APAP 
did not recrystallize even though the solubility limit was exceeded. Based on these 
results, amorphous APAP could exist in the crystalline portion of PEO, possibly at a 




Figure 4.32  Number of nuclei in the POM field of view (a 4.5 mm
2
 area) of PEO and 








































Under isothermal crystallization conditions, spherulitic growth rates were 
calculated from the slope of the spherulite diameter versus time plots. The results 
obtained show a good linear increase of spherulite diameter with crystallization time for 
all samples. The spherulitic growth rate G is found to decrease with increasing APAP 
content as shown in Figure 4.33. The decrease is appreciable only for the 10%APAP 
concentration sample, where APAP solid regions are suspected to exist. When a polymer 
contains “defects”, APAP in this case, these defects must be rejected from the crystals as 
long as they are sizable and cannot be accommodated by the lamellar folded chain 
growing crystallization regions.
[208]
 Only small size defects may be included in the 




 in the 
crystal have been proposed. There are many case examples of steric reasons for 
exclusion
[211-214]
 (short-chain branches formed by the comonomers of 1-butane, 1-hexane, 
or 1-octane in i-PP copolymers) as well as inclusion
[215-217]
 (stereo-defect in i-PP) in the 
literature papers. Figure 4.34 shows the growth rate data for a series of i-PP with different 
isotacticities. With decreasing isotacticies, the growth rates are significantly reduced, 
while the structural analysis (small angle X-ray scattering and transmission electron 
microscopy, which will be discussed in more details later) indicates that the stero-defects 
of i-PP are included in the crystals.
[216]
 In summary, both exclusion and inclusion 
mechanisms can slow down the growth rates as observed in the APAP-PEO system used 










Figure 4.34  A set of linear growth rates of i-PP having five different extents of 
isotacticities over a wide crystallization temperature Tc range. From top to bottom, 







































For the case of a melt-miscible polymer blend of a semi-crystalline and an 
amorphous polymer, the length scale over which the diluent polymer diffuses during 
crystallization is determined by the relationship between the diffusion coefficient of the 
amorphous polymer in the semi-crystalline polymer and the crystallization rate.
[218-221]
 
The diluent polymer can reside in interlamellar regions (amorphous layers between 
crystalline lamellae), interfibrillar regions (amorphous regions between stacks of 
lamellae) and interspherulitic regions,
[219]
 and the resulting segregation mechanisms are 
schematically illustrated in Figure 4.35. The difference between small molecular weight 
drugs and amorphous polymers is that the former, because of their size, are more 
favorable to be confined within the interlamellar regions, or even within the intralamellar 
regions. Having said this, the physical state of APAP is nevertheless unclear at this point. 
It might exist as amorphous clusters,
[155]
 crystalline particles with the unit cell dimension 







 or single molecules. Recently, Shekunov et al. reported that in the polymer 
synthesized from PEO crosslinked by polyurethane (PEO-PU), a hydrogel system, APAP 
was able to shift the SAXS peak (Figure 4.36) while the other model drug caffeine was 
not.
[155]
 The reason for the difference is because APAP can form strong hydrogen bonds 
with the PEO, leading to a PEO-APAP complex, while the intermolecular interactions 
between caffeine and PEO-PU are much weaker and therefore their effect on the polymer 
structure is less pronounced. The size of APAP, derived from SAXS, was estimated to be 
between 7-10 nm.  
At Tx of 30 
o
C when both PEO chain folding and APAP recrystallization rates are 





a. Interlamellar b. Interfibrillar c. Interspherulitic d. Intralamellar 
Figure 4.35  Possible modes of segregation in a binary blend that is miscible in the 
amorphous state and contains one crystallizing component, (a-c) adapted from the 
literature paper;
[219]
 (d) was proposed by the author, ● APAP. 
 
shape or Maltese pattern. POM images show that the spherulites are space-filled with no 
evidence of APAP interspherulitic accumulation even for 10%APAP-PEO (Figure 4.37). 
At Tx of 50 
o
C, however, the morphology of 10%APAP-PEO is more dendritic than 
spherulitic with large unfilled space in between spherulites. To determine if APAP is 
located in the interspherulitic regions, one may use micro-Infrared (IR) spectroscopy 
coupled with POM for determination. The POM locates the microprobe to the area for IR 
measuring, the dark unfilled space in Figure 4.37 (b) for example, and the IR will 
determine if APAP exists in that particular space. The physical state of the APAP can 
also be determined by comparing the peak positions in the IR spectra.
[32]
 
Since typical polymers are about 1000 nm long and the lamellar thickness is 
around 10 nm,
[23]
 it is possible for APAP to locate either in the intralamellar, 
internlamellar, interfibrillar, or all these three regions. The most commonly used 
characterization techniques to determine the additive’s location are SAXS and TEM. 
Recently, Zhu et al. have used SAXS to detect the increase of the long period, which is 







Figure 4.36  Characteristic SAXS correlation function obtained for the pure dry PEO-PU 
polymer; polymer saturated with 6.6% acetaminophen and saturated with 6.4% caffeine. 
The parameter Lp defines the long period (the sum of the thickness of the crystalline 






Figure 4.37  POM images of 10%APAP-PEO at Tx of (a) 30 
o








chlorpropamide(CPM)/PEG(MW 3350) solid dispersion system as compared to pure 
PEG.
[222]
 As can be seen in Figure 4.38, the diffraction peak in the SAXS profile of 
20%CPM/PEG shifted to a smaller scattering vector, which corresponded to a larger long 
period of 11.8nm. The long period of once-folded pure PEG was 11.0 nm. The diffraction 
peak shifted even further to a smaller scattering vector for the 40%CPM/PEG, where the 
long period increased to approximately 14 nm. TEM images also indicated more 
extensive amorphous regions between lamellae of PEO N10 after ketoprofen was melt-
mixed into the matrix.
[223]
 In Figure 4.39, the darker stained bands indicate the 
amorphous phase between crystallites. Although the morphology of the two types of 
samples resemble each other, the amorphous region of ketoprofen/PEO that lie between 
the crystalline regions are wider, suggesting that ketoprofen in the dispersion resides in 
the amorphous region. 
It is important to determine APAP’s location in the crystalline portion of PEO 
since the drug diffusion can be hindered due to the presence of crystallites.
[85]
 The deeper 
APAP is buried in the PEO chains, the harder it is for APAP to be released during 
dissolution. Future work to determine the location and physical state of the APAP 
(amorphous or crystalline) and its physical size following the PEO chain folding will be 
very interesting. Unfortunately, the author’s efforts to locate a SAXS have failed. As a 
result, this part of the work will be continued in 2012. Nevertheless, the number of 
spherulitic nuclei determined from the POM experiments is a good indication of drug-
polymer miscibility. At 30 
o
C, the APAP’s solubility in PEO is about 1% because the 
number of nuclei is the same for pure PEO, 0.1%APAP-PEO and 1%APAP-PEO. Based 
on the same criteria, the solubility at 50 
o




concluded that the solubility at room temperature was less than 10% by using various 
characterization techniques such as SEM, XRD, DSC and DMTA. As compared to those 
techniques, the POM method has its advantage of being efficient because there is no need 
to wait for APAP’s recrystallization from PEO, a phenomenon that could take days if not 
months to be detectable especially for samples with low APAP concentration. This is a 
simple and straight-forward way to estimate a drug’s solubility in a semi-crystalline 
polymer at temperatures below the polymer’s melting point.  
 
 














To study the spherulitic growth kinetics, more spherulitic growth rates were 
measured and plotted in Figure 4.40. The Hoffman-Lauritzen (HL) theory was applied by 
utilizing Equation (4.13) and results were plotted in Figure 4.41. Only one regime of 
crystal growth is observed for each sample. Cheng et al. reported that for pure PEO 
regime III takes place for degrees of supercooling larger than 17.5 K, and regime II takes 
place for supercoolings between 10 and 17.5 K (Figure 4.42).
[92]
 Regime I growth 
appears to be confined to a very narrow range of ∆T between 8.5 and 10 K. The 
supercooling ranges used here are 16.1 K < ∆T < 22.1 K for pure PEO, 19.3 K < ∆T < 
25.3 K for 2%APAP-PEO, 23 K < ∆T < 29 K for 10%APAP-PEO, and 32.1 K < ∆T < 
38.1 K for 20%APAP-PEO. The supercooling ranges for all samples are close to or larger 






Figure 4.40  Isothermal spherulitic growth rate G (µm/s) vs. crystallization temperature 




Figure 4.41 Hoffman-Lauritzen (HL) plots for PEO (◊), 2%APAP-PEO (□), 10%APAP-

























































Kg is the slope of the linear HL function in Figure 4.41 and the obtained values for 
APAP-PEO systems are listed in Table 4.5. The nucleation constant Kg increases with 
APAP concentration, with 2%APAP-PEO being 1.6 times, 10%APAP-PEO being 3 
times, and 20%APAP-PEO being 5.6 times of pure PEO. Using the stem width a0 = 




 as previously determined by Godovsky et 
al.,
[224]
 the products of lateral and folding surface free energies σσe are calculated based 
on Equation (4.12). The lateral surface free energy σ is estimated by the Thomas-Stavely 
relationship
[225]
 and it is σ = 0.1a0(∆Hf) = 9.8 erg/cm
2
. The folding surface free energy σe 
as well as the work of chain folding q = 2 σeA,
[181]
 where A is the molecular cross-
sectional area and is 0.214 nm
2
 for PEO, are then calculated and listed in Table 4.5. The 
σe value for pure PEO is in good agreement with the σe being 26-28 erg/cm
2 
of PEO in 
regime III reported by Cheng.
[92]
 Cheng et al. have observed that the folding surface free 
energy σe of phenoxy-end-capped PEO is about 1.3 times higher than that of PEO,
[91]
 and 
Huang et al. have found the σe of single C60(fullerene)-capped PEO is of about 1.8 times 
larger than that of PEO, while that of double C60-capped PEO is about 2.5 times larger 
than that of PEO.
[197]
 In this study, the σe values of 2%, 10% and 20%APAP-PEO are 
about 1.6 times, 2.9 times and 5.4 times those of pure PEO, respectively, indicating 
strongly that chain folding is much more difficult after APAP is incorporated into PEO. 
Since the APAP “defects” are either excluded or included in the PEO crystals, it is 







Figure 4.42 Hoffman-Lauritzen (HL) plots for PEO crystallized from the melt. From top 




Table 4.5  Kinetic Data of PEO and APAP-PEO Blends from POM Study 
Sample Kg (III)(10
4 K-2) σσe (erg
2/cm4) σe (erg/cm
2) q (kJ/mol) 
PEO 5.9 278 28.2 7.3 
2%APAP-PEO 9.4 435 44.2 11.4 
10%APAP-PEO 17.8 818 83.1 21.4 
20%APAP-PEO 33.1 1499 152.3 39.2 
 
 
4.5.4 Macroscopic Properties – Differential Scanning Calorimetry (DSC) 
An example of the isothermal DSC curves at various crystallization temperatures is 
presented in Figure 4.43. The Avrami parameter n values and the overall crystallization 
rate constants Kn are obtained from the double logarithmic plots of Equation (4.15). The 
log[-ln(1-X(t))] versus log t plots are shown in Figure 4.44. The Avrami exponents n for 





Figure 4.43 Isothermal DSC curves for 10%APAP-PEO at various Tcs.  
 
Figure 4.44 Avrami analysis of 10%APAP-PEO crystallized at various Tcs. 
 
Since no systematic variation of n with composition or temperature is found, the 
crystal growth control mechanism is very likely to be the same for all samples. Based on 
Schultz’s summary results in Table 4.4,
[203, 204]












































heterogeneous nucleation, with the rate limiting step being diffusion of polymer 
molecules to or from the growth surface.  
The overall crystallization rate constant Kn is a combination of linear growth rate 
and nucleation density (rate). When the nucleation is instantaneous, the linear growth rate 
G is related to Kn by the simple relation G ∝ Kn1/n, as shown in the early work of 
Mandelkern, where n is the Avrami exponent.
[226]
























  (4.17) 
Kn and n, calculated from Avrami analysis, are used in the plot of Figure 4.45 
based on Equation (4.17). Since all supercooling ∆Ts are larger than 17 K as shown 
earlier, regime III is used to analyze the kinetic data. Table 4.6 lists the values of Kg, 
folding surface free energies σe, and the work of chain folding q. The values are in good 
agreement from those obtained from the POM study. σe and q for the 2, 10% and 
20%APAP-PEO are 1,4, 3.3 and 6.1 times that of pure PEO, respectively. In summary, 
incorporation of APAP makes the PEO chains behave in a “stiffer” fashion and makes it 
more difficult to fold in the process of crystallization.  
The efficiency of nucleating agents is usually estimated from the changes of the 
crystallization temperature (Tcp) by cooling a polymer sample from the melt. Upon 
cooling, the sample will crystallize at a given temperature, and an effective nucleating 
agent will cause Tcp of the homopolymer to increase, with a higher temperature 
corresponding to an increased level of nucleation.
[227-230]
 Figure 4.46 shows the Tcp of 
isotactic polypropylene (iPP) doped with three different nucleating agents, 





Figure 4.45  (lnKn)/n – ln∆T + U
*
/R(Tc-T∞) vs. 1/Tc∆Tf for PEO (◊), 2%APAP-PEO (□), 
10%APAP-PEO (Δ) and 20%APAP-PEO (×). Kn and n are calculated from Avrami 
analysis of isothermal DSC. 
 
Table 4.6 Kinetic Data of PEO and APAP-PEO Blends from DSC Study 
Sample Kg (III)(10
4 K-2) σσe (erg
2/cm4) σe (erg/cm
2) q (kJ/mol) 
PEO 5.1 240 24.3 6.3 
2%APAP-PEO 7.0 325 33.1 8.5 
10%APAP-PEO 17.3 796 80.9 20.9 
20%APAP-PEO 32.4 1467 149.1 38.4 
 
 
Figure 4.46  Comparison of the efficiency of the three nucleating agents. Effect of 
nucleating agent content on the peak temperature of crystallization of iPP. (○) PVCH, (□) 





































and a traditional commercial nucleating agent NA21 E.
[227]
 It is seen that all three agents 
can increase the Tcp and promote the nucleation of iPP. At a nucleating agent 
concentration of 200 ppm, the nucleating effect increases in the following order of M 
3988 < NA21 E < PVCH judging from Tcp increase. The Tcp increase resulting from 200 
ppm of M 3988 is only 3 
o
C while for the other two nucleating agents it is more 
pronounced and is around 13 
o
C and 20 
o
C.  Thus, it is not surprising to see in their POM 
results, Figure 4.47, that M 3988 is a poor nucleating agent allowing for the few 
nucleated spherulites to grow to large sizes, which would render the i-PP opticality, not 





Figure 4.47  Structure development in the presence of 200 ppm of the three nucleating 
agents studied. Polarized microscope images taken at Tc = 130 
o
C on quenched samples; 







The Tcps and enthalpies of PEO containing different APAP concentration are 
plotted in Figure 4.48. The Tcps are basically the same for PEO and low APAP 
concentration samples, which are 41.1, 41.4, 41.4 and 41.5 
o
C for PEO, 0.1%, 1% and 
2%APAP-PEO, respectively. The Tcps of 10% and 20%APAP-PEO samples, however, 
are 36.9 and 33.7 
o
C, respectively, substantially lower. Additionally, the crystallization 
enthalpy is reduced from 147.2 J/g for pure PEO to 134.8, 127.4 and 117.2 J/g for 0.1%, 
10% and 20%APAP-PEO, respectively. The results show that APAP decreases the 
nucleation efficiency and inhibits the crystallization of PEO, which is consistent with 
previous kinetic result conclusions that the fold surface free energy σe is increased and the 
chain folding of PEO becomes more difficult with increasing APAP content. 
 
Figure 4.48 The crystallization temperature (Tcp) and enthalpy (∆Hc) during non-






































































CONTRIBUTIONS, CONCLUSIONS AND PROPOSED FUTURE WORK 
 
The main objective and contribution of the thesis was to explore and develop novel and 
rather straight-forward experimental techniques for determining the solubility of APIs in 
polymer excipients at both hot-melt mixing processing temperatures, where the API solid 
dispersions/solutions are formed, and at ambient temperature, where the resulting oral 
dosages are stored and used. Knowledge of the increased temperature solubility, as well 
as the degree to which the API/excipient solid dispersion is able to remain this high 
solubility stably over its shelf life, is of paramount importance in understanding the 
emerging field of pharmaceutical hot-melt mixing/extrusion. Thus, developing novel and 
straight-forward solubility characterization methods at both processing and ambient 
temperatures, which are appropriate for such temperature sensitive material systems and 
which borrow techniques from the field of polymer rheology and thermomechanical 
properties characterization, have the potential of advancing this field more rapidly. 
 Solid dispersions of a model drug, acetaminophen (APAP), and a pharmaceutical 
grade polymer excipient poly(ethylene oxide) (PEO) of Mw= 100,000 g/mol, were 
prepared by hot-melt mixing. The main reason for choosing PEO, which is semi-
crystalline (80% crystallinity), instead of a totally amorphous polymer excipient was to 
have the opportunity to explore the ambient temperature solubility of APAP in both the 






A novel rheological method measuring the viscosity of drug-polymer melts of different 
API concentrations at temperatures above the polymer’s melting point or glass transition 
temperature, but below the drug’s melting point has been developed to determine the 
drug’s solubility in the polymer. Below that solubility limit, the viscosity of the molten 
mixture will decrease with increasing drug concentration denoting the plasticizing effect 
of the API. Above the solubility limit, the viscosity will increase with increasing drug 
concentration denoting the formation of a suspension created by API particles, which are 
able to dissolve at that temperature. Thus, the drug concentration corresponding to the 
minimum viscosity is the solubility at the specific temperature. The method is powerful, 
using accurate rheometers which do not expose the polymer excipient to high temperature 
for long time, is conducted under N2, and which, therefore, can be applied to investigate 
many temperature sensitive drug-polymer systems. Furthermore, very few assumptions 
are made in the experimental study and results analysis. The solubility data determined 
rheologically can be used to optimize the HME processing temperature “window” in 
order to achieve a fully miscible drug-polymer system with the minimum risk of 
degradation. 
 As mentioned above, a semi-crystalline polymer was used as the excipient in this 
thesis work. Such a polymer allows for the use of polarized optical microscopy to study 
the polymer/drug spherulitic nucleation and growth rates, and morphology. As an 
example, the number of spherulitic nuclei can be used to determine a drug’s solubility in 
the polymer at temperatures below the polymer’s melting point, e.g., ambient 




the spherulites will deteriorate with increasing drug concentration. Above the solubility 
limit, the number of spherulitic nuclei will increase dramatically with increasing drug 
concentration, due to the fact that the supercooled API acts as a nucleating agent. The 
method only requires a hot-stage polarized microscope, and thus it is easily accessible 
and straight-forward. It is the first method that can determine a drug’s solubility in a 
semi-crystalline polymer accurately. As compared to other characterization techniques 
such as SEM, XRD, DSC and DMTA, the POM method has its advantage of being 
efficient because there is no need to wait for drug’s recrystallization from the semi-
crystalline polymer, a phenomenon that could take days if not months to be detectable 
especially for samples with low drug concentration. 
 
5.2 Conclusions 
Processing HMM conditions were optimized and fixed in order to focus the study on 
material properties. Rheological, microscopic and thermal methods were used to measure 
APAP’s solubility in PEO at both hot-melt extrusion or hot-melt mixing processing 
temperatures and storage temperature. As mentioned above, the strain-controlled 
rheometer measured the viscosity of APAP-PEO and the solubility data were obtained 
from the critical point on the curve of viscosity vs. drug loading. The solubility of APAP 
in PEO was also obtained from measuring the glass transition temperature at different 
drug loadings. Results from the two methods agree with each other and are further 
confirmed by hot-stage optical microscopic observation. The Tm
mix
/Tm(PEO) diagram 
developed in this work, which is essentially a “phase diagram”, can be used to determine 




The apparent drug solubility at room temperature was estimated through Tg 
measurements using DSC and DMTA, SEM observations, and XRD analysis. The 
APAP-PEO system was found to be a very difficult system because the miscibility of the 
two components is very poor at room temperature even though the components can 
achieve a fully miscible molten polymeric state at processing temperatures. One major 
reason is that PEO is a semi-crystalline polymer with a high tendency to recrystallize 
once the temperature drops below its melting point (62 
o
C). The apparent drug solubility 
after a month’s storage was estimated to be between 5-10%. All samples with APAP 
concentration ≥ 10% showed extensive APAP recrystallization. For 20% and 30%APAP-
PEO, APAP recrystallized almost instantaneously upon cooling to room temperature and 
the recrystallization process slowed down to an undetectable rate after one day. For the 
10%APAP-PEO system, the recrystallization process was found to be slower. However, 
the size and shape of the APAP crystalline particles formed by recrystallization were 
independent of the drug loading and did not change with increasing storage time. APAP’s 
recrystallization was found to be sensitive to the presence of the nanoclays melt-mixed 
into the APAP-PEO system during HMM. XRD spectra showed that nanoclays facilitated 
APAP’s recrystallization.  
A model using Flory-Huggins lattice theory and thermodynamic mixture phase 
equilibria was utilized to predict APAP’s solubility in PEO. The interaction parameter χ 
was calculated to be -1.65 from the depression of drug’s melting point determined from 
the Tm
mix
/Tm(PEO) diagram. The drug’s solubility in amorphous PEO was estimated to be 
11.7% at 300 K. Since PEO is a semi-crystalline polymer with crystallinity of 80%, the 




part of PEO. The solubility of APAP in PEG 400 was calculated to be 14.6% by using the 
same χ of -1.65, while the experimental measurement was 17.1%. The good match 
between the experimental and calculated data suggests that the χ for APAP-PEO 
calculated from the melting point depression method is a reasonable estimate.  
The nucleation and crystallization behavior of PEO was altered by the 
incorporation of APAP. At high crystallization temperature (50 
o
C), pure PEO, 
0.1%APAP-PEO, 1%APAP-PEO and 10%APAP-PEO had the same low number of 
spherulitic nuclei, indicating that APAP and PEO were fully miscible for all the 
compositions. At low crystallization temperature (30 
o
C), the number of nuclei for 
10%APAP-PEO was dramatically higher, suggesting that APAP was oversaturated and, 
therefore, recrystallized and acted as a nucleating agent. The fact that 1%APAP-PEO had 
more nuclei than PEO did at 40 
o
C hinted that the solubility was less than 1%. The reason 
for 1%APAP-PEO to have the same amount of nuclei as PEO at 30 
o
C was attributed to 
the low molecular mobility at that temperature so that APAP did not recrystallize even 
though the solubility limit was exceeded. Based on the results, amorphous APAP could 




The impact of the interaction parameter and the polymer MW on the Gibbs free 
energy of mixing ΔGm was investigated. The χ, which is controlled by the drug-polymer 
interaction, was found to play an important role while the polymer MW showed 
negligible effect on ΔGm. The drug’s solubility could be altered noticeably by the change 




a good indicator for preliminary polymer screening. The polymer that reduces the melting 
point the most, is likely to be most miscible with the drug. 
The releasing rate of APAP was slowed down significantly after melt-mixing with 
PEO. Nanoclay-containing samples presented much slower dissolution rates compared to 
both the drug powder and melt-mixed APAP-PEO. Data analysis of the dissolution 
results suggests that the drug’s release mechanism changes from an erosion dominant 
mode to a diffusion dominant one, due to the addition of nanoclays. The results suggest 
that nanoclays may be utilized to tailor the drug’s releasing rate. 
The crystallization behavior of pure PEO and APAP-PEO mixtures was studied 
by using polarized optical microscopy, isothermal DSC and nonisothermal DSC. Solvent 
evaporation method was utilized to prepare clean APAP-PEO and PEO films. The 
equilibrium melting temperature 0
m
T  was found to increase with APAP concentration by 
using the Hoffman-Weeks equation. At high crystallization temperature (50 
o
C), the 
Maltese cross pattern and symmetry of the PEO spherulites were disrupted in the 
presence of 10%APAP. At low crystallization temperature (30 
o
C), 10%APAP-PEO had 
significantly more spherulitic nuclei as compared to pure PEO, 0.1%APAP-PEO and 
1%APAP-PEO. The morphological, spherulitic growth and number of spherulitic nuclei 
analysis appears to be a promising, simple and novel method to determine a drug’s 
solubility in a semi-crystalline polymer at temperatures below polymer’s melting point 
and close to ambient. 
An extensive spherulitic nucleation and growth kinetics study using the classical 
theoretical relationships, e.g., the Hoffman-Lauritzen (HL) and Avrami theories, was 




APAP concentration. HL theory was used to calculate the kinetic parameters. Both POM 
and DSC analysis yielded similar values for the nucleation constant Kg as well as the fold 
surface free energy σe and work of chain folding q. The values of σe and q increased with 
APAP concentration, indicating that the chain folding of PEO became much more 
difficult because of hindering by APAP. Non-isothermal DSC showed that APAP 
reduced the nucleation efficiency and inhibited the crystallization of PEO, which is 
consistent with the kinetic results that the chain folding of PEO became more difficult 
with increasing APAP concentration. 
 
5.1 Proposed Future Work 
The spherulitic nucleation and growth kinetics study suggests that APAP is mostly likely 
working as a chemical defect and is either rejected from or included in the PEO crystals 
during chain folding. However, the physical state (amorphous, crystalline) and the size of 
the APAP are unknown due to the detection limit of the instruments for the crystallization 
study. SAXS, TEM and micro-IR spectroscopy coupled with POM can be utilized in the 
future to analyze the location of the APAP in PEO spherulites, namely interspherulitic, 
interfibrillar, interlamellar or intralamellar. By determining the location of APAP, it is 
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